Track market-moving stories before they get noisy

Analysts with JPMorgan Chase upgraded Intel (INTC -0.70%) to neutral from underweight on Monday, Oct. 19, citing growing agentic artificial intelligence (AI) workloads and tight supplies of advanced chips. The chipmaker's stock gained around 2% that day, ending at $92.03.

Even after that bounce, shares are around 35% under their record close of $140.94 on June 22. And most of the drop has happened lately. The stock still closed above $127 as late as Sept. 24.

Sure, an upgrade to neutral isn't a call to buy, and I wouldn't buy or sell a stock based on an analyst's rating anyway. What matters more is how much investors now pay for what Intel earns. And by that measure, the stock has gotten far cheaper than its 35% drop suggests.

Image source: Intel.

Intel's earnings have nearly doubledWhen Intel set its record in June, its four most recently reported quarters came to non-GAAP (adjusted) earnings per share of just $0.57. That figure included a loss of $0.10 a share in the second quarter of 2025.

At $140.94, then, investors were paying almost 250 times Intel's adjusted earnings for the previous four quarters.

Intel's second-quarter results, released in July, changed that. Revenue rose 25% year over year to $16.1 billion, accelerating sharply from 7% growth in the first quarter and a 4% fall in the fourth quarter of 2025. And adjusted earnings per share climbed to $0.42, up from $0.15 in the fourth quarter of 2025 and $0.29 in the first quarter of 2026.

Combined, the past four reported quarters now total $1.09 a share in adjusted earnings -- nearly double the June number.

At around $92 as I write, Intel trades at about 84 times these earnings. It's still a steep price-to-earnings ratio. But it's around a third of where the ratio was at the record, even though the share price fell only about 35%. In other words, rising profits did more to cut the stock's price-to-earnings ratio than the falling share price did.

Intel's GAAP results look much worse. On that basis, the company lost $2.16 a share for the second quarter. But a non-cash charge of $2.45 a share more than accounted for the loss. The charge is linked to Intel stock held in escrow for the U.S. government under its CHIPS Act deal, so I'm leaning on the adjusted numbers here.

A step backThe next step is a smaller one, though. For the third quarter, management's guidance calls for $0.38 a share in adjusted earnings. This would be up 65% from $0.23 for the third quarter of 2025, but down from the second quarter's $0.42.

Revenue growth may slow, too. The midpoint of Intel's guidance range from $15.8 billion to $16.8 billion implies growth of around 19% year over year, after 25% for the second quarter.

If Intel earned $0.38 a share every quarter over a year, it'd make around $1.52. At around $92 a share, the stock would cost about 60 times that annual pace of earnings.

Demand for AI computing doesn't look like the issue.

"AI-driven compute continues to strengthen, and to support expected growth this year and next across products and foundry, we are meaningfully increasing our investments in equipment, clean room space, and substrates," CFO Dave Zinsner said in Intel's second-quarter earnings release.

Turning that demand into steadily rising earnings per share is what Intel still needs to prove. And the third-quarter guidance suggests the climb might not continue every quarter.

INTC Intel$91.05-$0.64 (-0.70%)

NASDAQ · As of 9:54 AM ET 10/21/26

Is the drop big enough?Based on expected earnings for 2027, Intel trades at around 44 times earnings. That price-to-earnings ratio arguably assumes Intel's profits can keep climbing well past the third quarter's pace. Intel posts third-quarter results on Thursday, Oct. 29, which might show whether the $0.38 forecast was cautious or the start of a flatter stretch.

Does the 35% drop make Intel stock a buy? I don't think so yet. The drop, plus a far stronger second quarter, has moved the price a lot closer to what Intel earns. But at around 84 times adjusted earnings in the past four quarters, the stock still prices in lots of growth that hasn't come yet.

I'd want to see adjusted earnings per share climb back above the second quarter's $0.42 before considering the stock at this price.

Oracle Health and Oracle Fusion Cloud Applications will help bring data together, streamline work, and support a more connected patient experience

, /PRNewswire/ -- Southwest General, a private, not-for-profit, acute care hospital in Middleburg Heights, Ohio, is expanding its relationship with Oracle. Building on its use of Oracle Health Foundation EHR and the recent integration of Oracle Health AI Agents, clinical note capabilities, to help automate routine administrative tasks and give physicians more time with patients, Southwest General is adopting Oracle Health Patient Accounting, Oracle Health Data Intelligence, and Oracle Fusion Cloud Applications. These applications will help unify clinical, financial, and operational information, simplify workflows, and support informed care decisions across the organization.

As an independent community-focused health center, Southwest General is working to alleviate administrative complexity created by disconnected financial, operational, and health information systems. By expanding its use of Oracle technology across the enterprise, Southwest General will build an integrated environment that helps its team access the right information when and where it needs it, reduce manual processes, and spend more time supporting patients throughout their healthcare journeys.

"At Southwest General, we are taking control of our digital transformation to build an environment that works better for our patients and for the people who care for them," said Jae Zayed, chief digital and information officer, Southwest General. "With Oracle, we are bringing our clinical, financial, and operational systems into a shared environment to better equip clinicians and staff with the information and tools they need to focus on what matters most—delivering high-quality care. This investment will help us improve the experience for our team and for the patients and families who rely on us."

Southwest General will use Oracle Health Patient Accounting to create a comprehensive view of key financial information for its revenue cycle team. By bringing billing, payments, claims, and account information into one system, Oracle Health Patient Accounting can help reduce manual work, support accurate billing and faster payment processing, and make it easier to address patient questions. Streamlining these processes can improve the experience for both patients and staff while supporting stronger revenue operations.

Oracle Health Data Intelligence will help Southwest General bring health data together in a central environment, making relevant patient information easier for its care team to access. With a more complete view of information they need, clinicians can make more informed care decisions, better coordinate care, and identify opportunities to improve the patient experience.

To complement these solutions, Southwest General plans to adopt the full Oracle Fusion Applications suite including: Oracle Fusion Cloud Enterprise Resource Planning (ERP), Oracle Fusion Cloud Enterprise Performance Management (EPM), Oracle Fusion Cloud Human Capital Management (HCM), Oracle Fusion Cloud Supply Chain & Manufacturing (SCM), and Oracle Fusion Cloud Customer Experience (CX). Together, these AI-powered enterprise applications will help Southwest General standardize processes, improve visibility into enterprise performance, and establish a scalable foundation for continued innovation.

"Our community deserves care and service supported by modern capabilities that help us meet today's healthcare challenges," said Darrell Lentz, chief financial officer, Southwest General. "Oracle is giving us the platform and unified data environment to leapfrog years ahead of industry leaders, helping our team make more contextually aware care decisions, manage the revenue cycle with greater confidence, and operate with greater agility. This is about raising the bar for the care and service we provide to our community."

"Healthcare organizations need connected systems that make it easy for people to do their best work and focus on the people they serve," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "By connecting care delivery, revenue cycle, and enterprise operations with Oracle, Southwest General is equipping its team to work from a more complete picture and helping create a more coordinated, responsive experience for its community. Oracle is proud to support its continued leadership and innovation."

To learn more about how Oracle Health is helping transform healthcare, visit www.oracle.com/health.

About Southwest General
Southwest General Health Center is a private, not-for-profit, 368-bed acute care hospital located in Middleburg Heights, Ohio. Founded in 1920, Southwest General has a long-standing reputation for clinical excellence, compassionate care, and personalized service. The hospital is home to nationally recognized physicians and offers comprehensive, high-quality care supported by advanced technology and a commitment to continuous improvement. Dedicated to serving the communities southwest of Greater Cleveland, Southwest General partners with patients and families to deliver exceptional care close to home.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit www.oracle.com.

About Oracle Fusion Cloud Applications
Oracle Fusion Cloud Applications provide an integrated suite of AI-powered cloud applications that enable organizations to execute faster, make smarter decisions, and lower costs. Oracle Fusion Applications include:

Oracle Fusion Cloud Enterprise Resource Planning (ERP): Provides a comprehensive suite of AI-powered finance and operations applications that help organizations increase productivity, reduce costs, expand insights, improve decision-making, and enhance controls. Oracle Fusion Cloud Human Capital Management (HCM): Provides a unified AI-powered HR platform that connects all people-related processes and data to help organizations automate tasks throughout the employee lifecycle, improve the employee experience, and give HR leaders actionable workforce insights. Oracle Fusion Cloud Supply Chain & Manufacturing (SCM): Provides a unified AI-powered platform that integrates supply chain and operations processes and helps organizations enhance resilience and quickly adapt to market changes. Oracle Fusion Cloud Customer Experience (CX): Provides a suite of AI-powered applications that help organizations manage marketing, sales, and service processes to win business, build stronger customer relationships, and improve customer experiences. Trademarks
Oracle, Java, MySQL, and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company, ushering in the new era of cloud computing.

SOURCE Oracle

Moody's (MCO - Free Report) came out with quarterly earnings of $4.14 per share, missing the Zacks Consensus Estimate of $4.25 per share. This compares to earnings of $3.92 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -2.59%. A quarter ago, it was expected that this credit ratings agency would post earnings of $4.24 per share when it actually produced earnings of $4.68, delivering a surprise of +10.38%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Moody's, which belongs to the Zacks Financial - Miscellaneous Services industry, posted revenues of $2.02 billion for the quarter ended September 2026, missing the Zacks Consensus Estimate by 2.02%. This compares to year-ago revenues of $2.01 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Moody's shares have lost about 7% since the beginning of the year versus the S&P 500's gain of 12.7%.

What's Next for Moody's?While Moody's has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Moody's was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.62 on $1.93 billion in revenues for the coming quarter and $16.92 on $8.28 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Miscellaneous Services is currently in the bottom 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Antalpha Platform Holding Company (ANTA - Free Report) , has yet to report results for the quarter ended September 2026.

This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of -64.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Antalpha Platform Holding Company's revenues are expected to be $11.45 million, down 45.6% from the year-ago quarter.

EBay (EBAY.O) will lay off about 9% of its workforce as the online marketplace ​looks to simplify operations and shift resources to its fastest-growing ‌areas, CEO Jamie Iannone told staff in a memo that was reviewed by Reuters.

A spokesperson for eBay confirmed the layoffs to Reuters on Wednesday.

The move will eliminate around ​1,100 jobs, based on the 12,300 employees eBay had at ​the end of last year. The company also let go ⁠about 6% of its workforce, or 800 employees, in February as part of ​efforts to streamline operations.

EBay has set itself apart from rivals by pushing ​into authenticated luxury goods, collectibles and refurbished products, which draw enthusiasts willing to pay more for valuable items. That has helped its shares rise nearly 40% this year, ​outperforming the benchmark S&P 500's around 12% gain.

"Our strategy is working," ​Iannone said in the memo, adding that "continuing to capture the significant opportunity ahead requires ‌us to ⁠make thoughtful choices about where we focus and invest."

He said affected staff would be informed in the coming days.

Shares of eBay were down 1.8% in premarket trading.

The company has this year also benefited from its $1.4 billion ​deal for fashion ​resale platform Depop, ⁠which expanded its reach among younger consumers and strengthened its position in the growing re-commerce market.

That helped eBay ​forecast third-quarter revenue above Wall Street estimates when it ​last posted ⁠results, in August. The company is slated to report latest earnings next week.

Those efforts have also caught the eye of GameStop CEO Ryan Cohen, who ⁠made ​an unsolicited $56 billion bid for the much ​larger eBay in May. EBay had rejected the offer, saying that it was "neither credible nor attractive."

Pinterest (PINS - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this digital pinboard and shopping tool company have returned +25%, compared to the Zacks S&P 500 composite's +0.7% change. During this period, the Zacks Internet - Software industry, which Pinterest falls in, has gained 1.9%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Pinterest is expected to post earnings of $0.50 per share, indicating a change of +31.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $2.06 for the current fiscal year indicates a year-over-year change of +28.8%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $2.35 indicates a change of +14.2% from what Pinterest is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Pinterest is rated Zacks Rank #4 (Sell).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Pinterest, the consensus sales estimate of $1.2 billion for the current quarter points to a year-over-year change of +14.4%. The $4.89 billion and $5.54 billion estimates for the current and next fiscal years indicate changes of +15.9% and +13.2%, respectively.

Last Reported Results and Surprise HistoryPinterest reported revenues of $1.18 billion in the last reported quarter, representing a year-over-year change of +18.2%. EPS of $0.43 for the same period compares with $0.33 a year ago.

Compared to the Zacks Consensus Estimate of $1.15 billion, the reported revenues represent a surprise of +2.39%. The EPS surprise was +19.44%.

Over the last four quarters, Pinterest surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Pinterest is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Pinterest. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Net Worth Advisory Group grew its position in Micron Technology, Inc. (NASDAQ:MU – Free Report) by 253.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,552 shares of the semiconductor manufacturer’s stock after acquiring an additional 1,113 shares during the period. Net Worth Advisory Group’s holdings in Micron Technology were worth $1,703,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Denali Advisors LLC bought a new position in Micron Technology during the 2nd quarter worth approximately $7,364,000. Castleark Management LLC bought a new stake in Micron Technology during the 1st quarter valued at $3,709,000. Oppenheimer & Co. Inc. raised its holdings in shares of Micron Technology by 16.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 48,520 shares of the semiconductor manufacturer’s stock worth $56,006,000 after acquiring an additional 6,702 shares during the last quarter. Legacy Wealth Management LLC MS raised its position in Micron Technology by 73.3% in the 2nd quarter. Legacy Wealth Management LLC MS now owns 3,544 shares of the semiconductor manufacturer’s stock valued at $4,091,000 after buying an additional 1,499 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC lifted its position in shares of Micron Technology by 2,461.4% during the second quarter. Franklin Street Advisors Inc. NC now owns 37,141 shares of the semiconductor manufacturer’s stock valued at $42,871,000 after purchasing an additional 35,691 shares in the last quarter. 80.84% of the stock is owned by institutional investors and hedge funds.

Micron Technology News Roundup Here are the key news stories impacting Micron Technology this week:

Positive Sentiment: Micron announced funding for Indium Corporation’s critical-minerals and high-purity materials processing expansion in New York. The investment, part of Micron’s planned U.S. supply-chain spending of up to $3 billion, is intended to improve access to materials needed for advanced memory production and reduce exposure to overseas supply disruptions. Micron Invests in New York Critical Minerals Processing With Indium Corporation Positive Sentiment: Bullish analysts continue to point to tight memory supply, rising contract prices, strong AI-related demand and a potential share repurchase program. Recent results and guidance also showed substantial revenue and earnings growth, supporting the view that Micron’s memory upcycle could extend through 2027 and beyond. Micron Stock Moves Higher: What’s Going On? Positive Sentiment: Some investors view MU as attractively valued relative to its earnings potential, with Wall Street highlighting its strong September-quarter performance, elevated memory prices and multiyear customer commitments as reasons for further upside. The Best Trillion-Dollar Stock to Buy Right Now, According to Wall Street Neutral Sentiment: Micron is scheduled to host a technology webinar on October 21, which could provide additional details on its AI-memory roadmap, manufacturing plans and demand outlook. Micron to Host Technology Webinar on Oct. 21 Negative Sentiment: A union at Micron’s Taoyuan facility in Taiwan plans to strike on October 22 over a bonus dispute. Because Taiwan is central to Micron’s DRAM production, investors are concerned about potential disruption, costs or shipment delays. Micron Union in Taiwan to Launch Strike Negative Sentiment: Memory stocks remain under pressure after a broader technology selloff revived fears that AI infrastructure spending and related valuations may be unsustainable. Investors are also questioning how long Micron’s unusually high profits can last as new capacity comes online and rivals respond. Micron Stock Falls Amid Three Warning Signals Negative Sentiment: China’s CXMT is progressing toward server-memory production, raising longer-term competitive and pricing concerns for Micron, particularly if Chinese suppliers expand despite export restrictions. Intel Versus Micron: Exposure to CXMT Insiders Place Their Bets In other news, EVP Sumit Sadana sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $934.29, for a total transaction of $14,014,350.00. Following the transaction, the executive vice president owned 191,021 shares in the company, valued at $178,469,010.09. This represents a 7.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Sanjay Mehrotra sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $968.90, for a total transaction of $38,756,000.00. Following the transaction, the chief executive officer directly owned 264,503 shares of the company’s stock, valued at $256,276,956.70. This represents a 13.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 124,424 shares of company stock valued at $116,629,966. 0.24% of the stock is currently owned by corporate insiders. Analyst Upgrades and Downgrades MU has been the topic of several research reports. TD Cowen restated a “buy” rating and issued a $1,600.00 target price on shares of Micron Technology in a research note on Thursday, October 1st. New Street Research upgraded shares of Micron Technology from a “neutral” rating to a “buy” rating and lifted their price target for the company from $470.00 to $1,250.00 in a report on Friday, August 14th. William Blair set a $1,300.00 target price on shares of Micron Technology in a report on Thursday, October 1st. Bank of America raised their price objective on shares of Micron Technology from $950.00 to $1,500.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Finally, Wolfe Research set a $1,500.00 price objective on Micron Technology in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, forty-one have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,407.88.

Get Our Latest Stock Analysis on Micron Technology

Micron Technology Trading Down 1.0% MU stock opened at $896.07 on Wednesday. Micron Technology, Inc. has a twelve month low of $192.40 and a twelve month high of $1,255.00. The company has a quick ratio of 2.94, a current ratio of 3.31 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 12.07, a price-to-earnings-growth ratio of 0.16 and a beta of 2.22. The firm’s fifty day simple moving average is $987.31 and its two-hundred day simple moving average is $872.76.

Micron Technology (NASDAQ:MU – Get Free Report) last released its quarterly earnings data on Wednesday, September 30th. The semiconductor manufacturer reported $33.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $31.77 by $1.65. Micron Technology had a net margin of 63.80% and a return on equity of 92.62%. The company had revenue of $54.23 billion during the quarter, compared to analysts’ expectations of $51.33 billion. During the same period in the previous year, the company earned $3.03 EPS. The firm’s quarterly revenue was up 379.1% on a year-over-year basis. Micron Technology has set its Q1 2027 guidance at 37.150-39.150 EPS. As a group, analysts anticipate that Micron Technology, Inc. will post 177.03 earnings per share for the current year.

Micron Technology Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 29th. Stockholders of record on Wednesday, October 14th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.1%. The ex-dividend date is Wednesday, October 14th. Micron Technology’s dividend payout ratio is currently 0.81%.

Micron Technology Profile (Free Report)

Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage products. Its portfolio includes dynamic random-access memory (DRAM), NAND flash memory, NOR flash memory, solid-state drives, memory modules, and other semiconductor solutions used in data centers, personal computers, smartphones, automotive systems, industrial equipment, and consumer electronics.

The company also provides high-bandwidth memory and other advanced memory technologies designed to support artificial intelligence, high-performance computing, networking, and graphics applications.

Featured Stories Five stocks we like better than Micron Technology Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding MU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Micron Technology, Inc. (NASDAQ:MU – Free Report).

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Kapitalo Investimentos Ltda lifted its position in shares of Micron Technology, Inc. (NASDAQ:MU – Free Report) by 2,644.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,442 shares of the semiconductor manufacturer’s stock after acquiring an additional 26,442 shares during the period. Micron Technology comprises approximately 2.1% of Kapitalo Investimentos Ltda’s holdings, making the stock its 9th largest holding. Kapitalo Investimentos Ltda’s holdings in Micron Technology were worth $29,229,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Denali Advisors LLC acquired a new position in Micron Technology during the 2nd quarter valued at about $7,364,000. Castleark Management LLC acquired a new stake in shares of Micron Technology in the first quarter valued at approximately $3,709,000. Oppenheimer & Co. Inc. increased its stake in shares of Micron Technology by 16.0% in the second quarter. Oppenheimer & Co. Inc. now owns 48,520 shares of the semiconductor manufacturer’s stock valued at $56,006,000 after purchasing an additional 6,702 shares during the period. Legacy Wealth Management LLC MS increased its stake in shares of Micron Technology by 73.3% in the second quarter. Legacy Wealth Management LLC MS now owns 3,544 shares of the semiconductor manufacturer’s stock valued at $4,091,000 after purchasing an additional 1,499 shares during the period. Finally, Franklin Street Advisors Inc. NC raised its holdings in shares of Micron Technology by 2,461.4% during the second quarter. Franklin Street Advisors Inc. NC now owns 37,141 shares of the semiconductor manufacturer’s stock valued at $42,871,000 after buying an additional 35,691 shares during the last quarter. 80.84% of the stock is currently owned by institutional investors.

Micron Technology Stock Down 1.0% MU stock opened at $896.07 on Wednesday. The firm’s 50-day moving average is $987.31 and its two-hundred day moving average is $872.76. The company has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 12.07, a price-to-earnings-growth ratio of 0.16 and a beta of 2.22. Micron Technology, Inc. has a 52 week low of $192.40 and a 52 week high of $1,255.00. The company has a current ratio of 3.31, a quick ratio of 2.94 and a debt-to-equity ratio of 0.03.

Micron Technology (NASDAQ:MU – Get Free Report) last posted its quarterly earnings data on Wednesday, September 30th. The semiconductor manufacturer reported $33.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $31.77 by $1.65. The business had revenue of $54.23 billion during the quarter, compared to analysts’ expectations of $51.33 billion. Micron Technology had a net margin of 63.80% and a return on equity of 92.62%. The business’s revenue was up 379.1% on a year-over-year basis. During the same period last year, the firm posted $3.03 earnings per share. Micron Technology has set its Q1 2027 guidance at 37.150-39.150 EPS. On average, analysts forecast that Micron Technology, Inc. will post 177.03 earnings per share for the current fiscal year. Micron Technology Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Thursday, October 29th. Shareholders of record on Wednesday, October 14th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.1%. The ex-dividend date is Wednesday, October 14th. Micron Technology’s dividend payout ratio is 0.81%.

Analysts Set New Price Targets Several equities analysts have recently issued reports on the company. HSBC boosted their price objective on Micron Technology from $1,100.00 to $1,700.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. The Goldman Sachs Group set a $1,250.00 target price on Micron Technology in a research report on Thursday, October 1st. Arete Research lifted their target price on Micron Technology from $852.00 to $1,500.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $1,200.00 target price on shares of Micron Technology in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. boosted their price target on Micron Technology from $550.00 to $1,540.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, forty-one have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Micron Technology presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,407.88.

Read Our Latest Research Report on MU

Key Stories Impacting Micron Technology Here are the key news stories impacting Micron Technology this week:

Positive Sentiment: Micron announced funding for Indium Corporation’s critical-minerals and high-purity materials processing expansion in New York. The investment, part of Micron’s planned U.S. supply-chain spending of up to $3 billion, is intended to improve access to materials needed for advanced memory production and reduce exposure to overseas supply disruptions. Micron Invests in New York Critical Minerals Processing With Indium Corporation Positive Sentiment: Bullish analysts continue to point to tight memory supply, rising contract prices, strong AI-related demand and a potential share repurchase program. Recent results and guidance also showed substantial revenue and earnings growth, supporting the view that Micron’s memory upcycle could extend through 2027 and beyond. Micron Stock Moves Higher: What’s Going On? Positive Sentiment: Some investors view MU as attractively valued relative to its earnings potential, with Wall Street highlighting its strong September-quarter performance, elevated memory prices and multiyear customer commitments as reasons for further upside. The Best Trillion-Dollar Stock to Buy Right Now, According to Wall Street Neutral Sentiment: Micron is scheduled to host a technology webinar on October 21, which could provide additional details on its AI-memory roadmap, manufacturing plans and demand outlook. Micron to Host Technology Webinar on Oct. 21 Negative Sentiment: A union at Micron’s Taoyuan facility in Taiwan plans to strike on October 22 over a bonus dispute. Because Taiwan is central to Micron’s DRAM production, investors are concerned about potential disruption, costs or shipment delays. Micron Union in Taiwan to Launch Strike Negative Sentiment: Memory stocks remain under pressure after a broader technology selloff revived fears that AI infrastructure spending and related valuations may be unsustainable. Investors are also questioning how long Micron’s unusually high profits can last as new capacity comes online and rivals respond. Micron Stock Falls Amid Three Warning Signals Negative Sentiment: China’s CXMT is progressing toward server-memory production, raising longer-term competitive and pricing concerns for Micron, particularly if Chinese suppliers expand despite export restrictions. Intel Versus Micron: Exposure to CXMT Insider Transactions at Micron Technology In other news, CEO Sanjay Mehrotra sold 40,000 shares of Micron Technology stock in a transaction on Friday, August 21st. The stock was sold at an average price of $968.90, for a total transaction of $38,756,000.00. Following the transaction, the chief executive officer directly owned 264,503 shares in the company, valued at approximately $256,276,956.70. This trade represents a 13.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Scott R. Allen sold 879 shares of Micron Technology stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $1,000.00, for a total value of $879,000.00. Following the transaction, the chief accounting officer owned 34,958 shares in the company, valued at approximately $34,958,000. This trade represents a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 124,424 shares of company stock valued at $116,629,966. 0.24% of the stock is currently owned by company insiders.

Micron Technology Profile (Free Report)

Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage products. Its portfolio includes dynamic random-access memory (DRAM), NAND flash memory, NOR flash memory, solid-state drives, memory modules, and other semiconductor solutions used in data centers, personal computers, smartphones, automotive systems, industrial equipment, and consumer electronics.

The company also provides high-bandwidth memory and other advanced memory technologies designed to support artificial intelligence, high-performance computing, networking, and graphics applications.

Recommended Stories Five stocks we like better than Micron Technology Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding MU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Micron Technology, Inc. (NASDAQ:MU – Free Report).

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Micron (MU +0.02%) stock has more than tripled so far in 2026, making it the fourth-best-performing stock in the S&P 500 (^GSPC +0.21%) this year. That's an impressive run, but for investors, the past really doesn't matter; only the future.

So, could Micron repeat this feat in 2027? One metric suggests that the answer to that question is yes.

Image source: The Motley Fool.

The memory chip shortage is far from over
Micron produces memory chips, which have become some of the most in-demand tech hardware due to their scarcity. The companies that manufacture them were not ready for the massive growth in demand generated by the artificial intelligence (AI) build-out, which has consumed all the supplies they could produce this year.

Memory chips are essentially commodity products. When demand significantly outpaces supply, prices soar -- and that's exactly what happened this year. However, Micron's input costs barely shifted, so the rising prices it can now charge are pure profit, and the stock skyrocketed as investors watched the company's top and bottom lines multiply.

MU Micron Technology$896.26+$0.19 (+0.02%)

NASDAQ · As of 9:47 AM ET 10/21/26

Moreover, this shortage isn't going to end soon.

On the latest earnings call, Micron's management team advised investors that it expects conditions in the memory chip market to be even tighter in 2027 and 2028 than they were in 2026. But Micron has been building new foundry lines in the meantime, and with more production capacity coming online in 2027, it will be able to manufacture more chips to sell at these higher price points, leading to significant additional profit growth.

This is reflected in Wall Street's outlook for the stock. Micron reported $75.52 in earnings per share during its fiscal 2026 (which ended in August), and management estimates Micron will generate a jaw-dropping $176.55 in earnings per share during its fiscal 2027.

Over the past couple of years, Micron's stock has usually traded in the neighborhood of 20 times earnings. Right now, it's a dirt cheap 12 times earnings because the market does not believe that this boom will last. However, its management team, which has access to more information about the tech sector than most investors, has already told anyone who will listen that the conditions leading to high memory demand and insufficient supply aren't going anywhere. As a result, the stock looks undervalued.

MU PE Ratio data by YCharts.

If Micron only meets analysts' expectations for its fiscal 2027, then in order to trade at just 15 times earnings next fall, the stock would have to triple. If it trades at 20 times earnings at that point, then the stock will have quadrupled from here.

The market's bearishness about the long-term outlook for AI spending has investors leaving obvious money on the table when it comes to a stock like Micron. Now is the time to take advantage of that mistake and buy Micron stock on sale, as it has major upside potential.

Over the last year, memory chip manufacturers have benefited from extraordinary demand for artificial intelligence (AI). In particular, Micron Technology (MU +0.02%) has witnessed its market capitalization propel from just $53 billion at the start of the AI revolution to more than $1 trillion today.

MU Market Cap data by YCharts

Despite its historic rally, investors should not assume Micron's growth is finished. As AI moves beyond data centers and becomes increasingly embedded in everyday products, the company stands to benefit from another wave of demand. What's encouraging is that you don't need thousands of dollars to participate in Micron's upside.

As of this writing (Oct. 20), Micron stock trades around $900. But investors can purchase fractional shares, allowing them to invest a fixed amount without buying an entire share. Let's assess what could happen if you invested $150 in Micron every month between now and the end of 2030.

What tailwinds does Micron have? Micron manufactures DRAM, NAND flash memory, and high bandwidth memory (HBM). These products help computers process, access, and store information.

HBM is becoming particularly important because AI accelerators require vast amounts of memory to process queries efficiently. Micron is already shipping HBM4 products optimized for Nvidia's Vera Rubin architecture, positioning the company to benefit from the AI infrastructure build-out.

Importantly, Micron's long-run opportunity extends beyond Nvidia's GPUs. The proliferation of agentic AI, CPUs, robotics, and autonomous systems will create additional demand for memory and storage. As these applications become more sophisticated and move into production, they will inevitably require greater capacity to process information, store data, and handle complex workloads.

Consider the automotive industry as an example. Micron has already announced long-term supply agreements with General Motors and Ford Motor Company. These partnerships support next-generation vehicle platforms, including advanced driver-assistance systems and AI-powered experiences inside of cars.

Micron also forged agreements with automotive technology suppliers such as Qualcomm, DENSO, and Hyundai Mobis -- demonstrating how memory is becoming essential across applications beyond consumer devices and hyperscale data centers.

Image source: Micron Technology.

How big can Micron get? Micron currently boasts a market capitalization of roughly $1.03 trillion. I see a few reasons why the company could become significantly more valuable as AI infrastructure investments accelerate, fueling further demand for advanced memory.

First, AI systems are becoming more memory-intensive. As new processors enter production and companies deploy AI across enterprise applications, demand for HBM and advanced DRAM should continue growing.

Second, Micron is investing heavily in manufacturing capacity while securing longer-term strategic customer agreements. Higher-value products such as HBM should support more robust profitability than conventional DRAM, helping Micron turn growing demand into sustainable earnings growth.

Lastly, investors could begin valuing Micron differently as its role in the AI supply chain becomes more recognized and appreciated. Historically, memory manufacturers traded at modest valuation multiples because of their cyclical business models. However, increasingly sophisticated memory products, stickier customer relationships, and new use cases could support a more favorable long-term valuation.

Taken together, I think Micron could reach a $2.5 trillion market capitalization by December 2030. Compared with its current market cap, that represents 145% cumulative upside, equivalent to 24% annualized stock appreciation, or 1.8% per month when compounded.

While this is slightly aggressive, I think it's a reasonable upside scenario considering it's considerably below the stock returns Micron has already generated during the AI infrastructure supercycle. If I apply that projected growth rate to all 51 monthly investments of $150, the total contribution of $7,650 invested could finish 2030 worth approximately $12,400. That represents roughly $4,750 in investment gains, or 62% upside.

MU Micron Technology$896.26+$0.19 (+0.02%)

NASDAQ · As of 9:47 AM ET 10/21/26

Smart investors always think about the long term Of course, Micron's actual stock price won't move in a perfect line. Semiconductor stocks frequently experience sharp rallies and sell-offs, making short-term fluctuations difficult to predict. That's precisely what makes dollar-cost averaging appealing. Investors can build a position over a long-term time frame without attempting to identify the perfect entry price.

The bigger theme here is that Micron should continue benefiting from multiple secular growth tailwinds that can support additional stock price appreciation over the next several years. As AI becomes more integrated into computing, transportation, and everyday consumer products, demand for advanced memory should expand.

For this reason, I see Micron as a compelling buy-and-hold opportunity for patient investors right now.

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 Expands portfolio with key new product approvals , /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2026.

Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis. Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items. Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1. Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55. In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes. In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib). In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk —  the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation. In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease. "Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."

THIRD-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. 

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

5,504

958

1,853

—

2,687

International

7,509

1,304

1,452

1,614

3,139

Total reported

13,013

2,262

3,305

1,614

5,826

% Change vs. 3Q25

U.S.

28.0

7.9

109.2

n/a

6.6

International

6.2

3.1

6.2

6.8

7.2

Total reported

14.5

5.1

46.7

6.8

6.9

Total reported excl. foreign exchange impact

14.8

4.9

46.6

8.4

7.4

Comparable sales growth

7.0

4.9

6.4

8.4

7.8

    U.S.

7.9

7.9

8.4

n/a

7.6

    International

6.4

2.8

4.0

8.4

8.0

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

14,994

2,673

4,418

—

7,890

International

21,776

3,750

4,159

4,539

9,328

Total reported

36,770

6,423

8,577

4,539

17,218

% Change vs. 9M25

U.S.

17.7

(4.5)

72.0

n/a

7.1

International

8.2

1.1

6.3

9.3

11.7

Total reported

11.9

(1.3)

32.4

9.3

9.6

Total reported excl. foreign exchange impact

10.5

(2.1)

30.8

8.7

7.8

Comparable sales growth

5.2

(2.1)

3.8

8.7

8.2

    U.S.

4.7

(4.5)

4.9

n/a

8.1

    International

5.7

(0.3)

2.4

8.7

8.3

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Nutrition

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Pediatric

Adult

U.S.

958

577

381

International

1,304

486

818

Total reported

2,262

1,063

1,199

% Change vs. 3Q25

U.S.

7.9

11.0

3.5

International

3.1

6.4

1.3

Total reported

5.1

8.8

2.0

Total reported excl. foreign exchange impact

4.9

8.7

1.8

Comparable sales growth

4.9

8.7

1.8

    U.S.

7.9

11.0

3.5

    International

2.8

6.0

1.0

Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9 percent on a comparable basis in the third quarter.

Worldwide Nutrition results were driven by broad-based growth across the portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.

On a sequential basis, Worldwide Nutrition sales increased $118 million compared to the second quarter of 2026.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Pediatric

Adult

U.S.

2,673

1,613

1,060

International

3,750

1,428

2,322

Total reported

6,423

3,041

3,382

% Change vs. 9M25

U.S.

(4.5)

(4.8)

(4.0)

International

1.1

3.7

(0.5)

Total reported

(1.3)

(1.0)

(1.6)

Total reported excl. foreign exchange impact

(2.1)

(1.6)

(2.6)

Comparable sales growth

(2.1)

(1.6)

(2.6)

    U.S.

(4.5)

(4.8)

(4.0)

    International

(0.3)

2.4

(2.0)

Diagnostics*

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

1,853

389

938

526

International

1,452

1,049

30

373

Total reported

3,305

1,438

968

899

% Change vs. 3Q25

U.S.

109.2

6.3

n/a

1.1

International

6.2

5.1

n/a

1.0

Total reported

46.7

5.4

n/a

1.1

Total reported excl. foreign exchange impact

46.6

5.4

n/a

0.9

Comparable sales growth

6.4

5.4

13.8

0.9

    U.S.

8.4

6.3

13.9

1.1

    International

4.0

5.1

12.1

0.7

Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.

Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.

Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

4,418

1,113

1,921

1,384

International

4,159

3,015

62

1,082

Total reported

8,577

4,128

1,983

2,466

% Change vs. 9M25

U.S.

72.0

6.1

n/a

(8.9)

International

6.3

5.8

n/a

1.9

Total reported

32.4

5.9

n/a

(4.5)

Total reported excl. foreign exchange impact

30.8

4.0

n/a

(5.4)

Comparable sales growth

3.8

4.0

13.5

(5.4)

    U.S.

4.9

6.1

13.5

(8.9)

    International

2.4

3.2

15.0

(0.4)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Established Pharmaceuticals

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,614

1,195

419

Total reported

1,614

1,195

419

% Change vs. 3Q25

U.S.

n/a

n/a

n/a

International

6.8

9.0

1.1

Total reported

6.8

9.0

1.1

Total reported excl. foreign exchange impact

8.4

10.9

1.6

Comparable sales growth

8.4

10.9

1.6

    U.S.

n/a

n/a

n/a

    International

8.4

10.9

1.6

Established Pharmaceuticals sales increased 6.8 percent on a reported basis and 8.4 percent on a comparable basis in the third quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

4,539

3,448

1,091

Total reported

4,539

3,448

1,091

% Change vs. 9M25

U.S.

n/a

n/a

n/a

International

9.3

10.5

5.6

Total reported

9.3

10.5

5.6

Total reported excl. foreign exchange impact

8.7

10.4

3.6

Comparable sales growth

8.7

10.4

3.6

    U.S.

n/a

n/a

n/a

    International

8.7

10.4

3.6

Medical Devices

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

2,687

380

429

303

290

228

185

872

International

3,139

372

444

84

496

364

66

1,313

Total reported

5,826

752

873

387

786

592

251

2,185

% Change vs. 3Q25

U.S.

6.6

9.0

18.1

8.4

3.4

(11.1)

(5.6)

9.4

International

7.2

10.4

12.2

(2.7)

6.7

12.2

13.6

4.2

Total reported

6.9

9.7

15.0

5.8

5.4

1.9

(1.2)

6.2

Total reported excl. foreign exchange impact

7.4

10.0

15.5

6.0

5.7

2.6

(1.1)

6.7

Comparable sales growth

7.8

10.0

15.5

6.0

5.7

6.9

(1.1)

6.7

    U.S.

7.6

9.0

18.1

8.4

3.4

(2.3)

(5.6)

9.4

    International

8.0

11.0

13.1

(1.6)

7.1

13.5

13.9

4.9

Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a reported basis and 7.7 percent on a comparable basis.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

7,890

1,096

1,227

908

875

677

551

2,556

International

9,328

1,083

1,295

269

1,491

1,090

203

3,897

Total reported

17,218

2,179

2,522

1,177

2,366

1,767

754

6,453

% Change vs. 9M25

U.S.

7.1

10.4

16.0

10.2

5.2

(10.2)

(2.4)

9.3

International

11.7

13.9

14.5

7.9

8.0

16.1

18.1

10.5

Total reported

9.6

12.1

15.2

9.7

7.0

4.4

2.4

10.0

Total reported excl. foreign exchange impact

7.8

10.6

13.8

8.9

5.2

2.6

1.3

7.7

Comparable sales growth

8.2

10.6

13.8

8.9

5.2

6.5

1.3

7.7

    U.S.

8.1

10.4

16.0

10.2

5.2

(2.3)

(2.4)

9.3

    International

8.3

10.8

11.9

4.6

5.2

12.8

13.5

6.6

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%1.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.

Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Abbott Declares 411th Consecutive Quarterly Dividend
On Sept. 17, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott's Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

3Q25

% Change

Net Sales

$13,013

$11,369

14.5

Cost of products sold, excluding amortization expense

5,628

5,075

10.9

Amortization of intangible assets

841

420

n/m

Research and development

920

766

20.1

Selling, general, and administrative

4,266

3,051

39.8

Total Operating Cost and Expenses

11,655

9,312

25.2

Operating Earnings

1,358

2,057

(34.0)

Interest expense, net

297

44

n/m

Net foreign exchange (gain) loss

(6)

(17)

n/m

Other (income) expense, net

(164)

(150)

9.4

Earnings before taxes

1,231

2,180

(43.5)

Taxes on Earnings

311

536

(42.0)

1)

Net Earnings

$920

$1,644

(44.1)

Net Earnings excluding Specified Items, as described below

$2,477

$2,278

8.7

2)

Diluted Earnings per Common Share

$0.53

$0.94

(43.6)

Diluted Earnings per Common Share, excluding Specified Items, as described below

$1.42

$1.30

9.2

2)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock
Options

1,738

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

9M25

% Change

Net Sales

$36,770

$32,869

11.9

Cost of products sold, excluding amortization expense

15,843

14,397

10.0

Amortization of intangible assets

1,921

1,260

52.4

Research and development

2,579

2,207

16.9

Selling, general, and administrative

12,031

9,203

30.7

Total Operating Cost and Expenses

32,374

27,067

19.6

Operating Earnings

4,396

5,802

(24.2)

Interest expense, net

664

143

n/m

Net foreign exchange (gain) loss

(15)

(35)

n/m

Other (income) expense, net

(457)

(414)

10.2

Earnings before taxes

4,204

6,108

(31.2)

Taxes on earnings

1,279

1,360

(6.0)

1)

Net Earnings

$2,925

$4,748

(38.4)

Net Earnings excluding Specified Items, as described below

$6,789

$6,410

5.9

2)

Diluted Earnings per Common Share

$1.67

$2.70

(38.1)

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$3.88

$3.65

6.3

2)

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,743

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      841

$      (841)

$        —

Gross Margin

6,544

904

7,448

R&D

920

(28)

892

SG&A

4,266

(761)

3,505

Other (income) expense, net

(164)

4

(160)

Earnings before taxes

1,231

1,689

2,920

Taxes on Earnings

311

132

443

Net Earnings

920

1,557

2,477

Diluted Earnings per Share

$     0.53

$     0.89

$      1.42

Specified items reflect intangible amortization expense of $841 million, legal settlements of approximately $670 million and other net expenses of $178 million associated with acquisitions, restructuring actions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

3Q25

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      420

$     (420)

$        —

Gross Margin

5,874

470

6,344

R&D

766

(36)

730

SG&A

3,051

(47)

3,004

Other (income) expense, net

(150)

5

(145)

Earnings before taxes

2,180

548

2,728

Taxes on Earnings

536

(86)

450

Net Earnings

1,644

634

2,278

Diluted Earnings per Share

$     0.94

$      0.36

$      1.30

Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$     1,921

$    (1,921)

$        —

Gross Margin

19,006

2,033

21,039

R&D

2,579

(77)

2,502

SG&A

12,031

(1,662)

10,369

Other (income) expense, net

(457)

(30)

(487)

Earnings before taxes

4,204

3,802

8,006

Taxes on Earnings

1,279

(62)

1,217

Net Earnings

2,925

3,864

6,789

Diluted Earnings per Share

$      1.67

$      2.21

$     3.88

Specified items reflect intangible amortization expense of $1.921 billion, legal settlements of approximately $1.070 billion and other net expenses of $811 million associated with acquisitions, restructuring actions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

9M25

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$    1,260

$   (1,260)

$        —

Gross Margin

17,212

1,396

18,608

R&D

2,207

(83)

2,124

SG&A

9,203

(58)

9,145

Other (income) expense, net

(414)

(31)

(445)

Earnings before taxes

6,108

1,568

7,676

Taxes on Earnings

1,360

(94)

1,266

Net Earnings

4,748

1,662

6,410

Diluted Earnings per Share

$     2.70

$      0.95

$     3.65

Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown below: 

3Q26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$     1,231

$       311

25.3 %

1)

Specified items

1,689

132

Excluding specified items

$    2,920

$      443

15.2 %

3Q25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    2,180

$      536

24.6 %

2)

Specified items

548

(86)

Excluding specified items

$    2,728

$      450

16.5 %

1)

2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below: 

9M26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$   4,204

$    1,279

30.4 %

3)

Specified items

3,802

(62)

Excluding specified items

$   8,006

$     1,217

15.2 %

9M25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    6,108

$    1,360

22.3 %

4)

Specified items

1,568

(94)

Excluding specified items

$    7,676

$    1,266

16.5 %

3)

2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

4)

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Third Quarter Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

3Q26

3Q25

% Change vs. 3Q25

Non-GAAP

Abbott
Reported

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

13,013

40

13,053

11,369

851

(23)

12,197

14.5

7.0

U.S.

5,504

—

5,504

4,299

824

(23)

5,100

28.0

7.9

Intl

7,509

40

7,549

7,070

27

—

7,097

6.2

6.4

Total Diagnostics

3,305

(2)

3,303

2,253

851

—

3,104

46.7

6.4

U.S.

1,853

—

1,853

886

824

—

1,710

109.2

8.4

Intl

1,452

(2)

1,450

1,367

27

—

1,394

6.2

4.0

Total Cancer Diagnostics

968

—

968

—

851

—

851

n/a

13.8

U.S.

938

—

938

—

824

—

824

n/a

13.9

Intl

30

—

30

—

27

—

27

n/a

12.1

Total Medical Devices

5,826

22

5,848

5,448

—

(23)

5,425

6.9

7.8

U.S.

2,687

—

2,687

2,521

—

(23)

2,498

6.6

7.6

Intl

3,139

22

3,161

2,927

—

—

2,927

7.2

8.0

Total Structural Heart*

592

4

596

580

—

(23)

557

1.9

6.9

U.S.

228

—

228

256

—

(23)

233

(11.1)

(2.3)

Intl

364

4

368

324

—

—

324

12.2

13.5

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Nine Months Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

9M26

9M25

% Change vs. 9M25

Non-GAAP

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

36,770

706

(8)

(460)

37,008

32,869

2,369

(69)

35,169

11.9

5.2

U.S.

14,994

681

(8)

—

15,667

12,743

2,294

(69)

14,968

17.7

4.7

Intl

21,776

25

—

(460)

21,341

20,126

75

—

20,201

8.2

5.7

Total Diagnostics

8,577

706

—

(100)

9,183

6,480

2,369

—

8,849

32.4

3.8

U.S.

4,418

681

—

—

5,099

2,568

2,294

—

4,862

72.0

4.9

Intl

4,159

25

—

(100)

4,084

3,912

75

—

3,987

6.3

2.4

Total Cancer Diagnostics

1,983

706

—

(1)

2,688

—

2,369

—

2,369

n/a

13.5

U.S.

1,921

681

—

—

2,602

—

2,294

—

2,294

n/a

13.5

Intl

62

25

—

(1)

86

—

75

—

75

n/a

15.0

Total Medical Devices

17,218

—

(8)

(284)

16,926

15,712

—

(69)

15,643

9.6

8.2

U.S.

7,890

—

(8)

—

7,882

7,363

—

(69)

7,294

7.1

8.1

Intl

9,328

—

—

(284)

9,044

8,349

—

—

8,349

11.7

8.3

Total Structural Heart*

1,767

—

(8)

(31)

1,728

1,692

—

(69)

1,623

4.4

6.5

U.S.

677

—

(8)

—

669

753

—

(69)

684

(10.2)

(2.3)

Intl

1,090

—

—

(31)

1,059

939

—

—

939

16.1

12.8

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$          10

$             29

$         841

$           24

$        904

R&D

(7)

(5)

—

(16)

(28)

SG&A

(47)

(20)

—

(694)

(761)

Other (income) expense, net

(8)

(1)

—

13

4

Earnings before taxes

$           72

$             55

$         841

$          721

1,689

Taxes on Earnings (d)

132

Net Earnings

$      1,557

Diluted Earnings per Share

$        0.89

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.

c)

Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants, as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$           —

$             44

$         420

$            6

$         470

R&D

—

(19)

—

(17)

(36)

SG&A

(9)

(43)

—

5

(47)

Other (income) expense, net

7

—

—

(2)

5

Earnings before taxes

$            2

$            106

$         420

$           20

548

Taxes on Earnings (d)

(86)

Net Earnings

$         634

Diluted Earnings per Share

$        0.36

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$          44

$             40

$        1,921

$           28

$       2,033

R&D

(18)

(15)

—

(44)

(77)

SG&A

(533)

(54)

—

(1,075)

(1,662)

Other (income) expense, net

(9)

(4)

—

(17)

(30)

Earnings before taxes

$         604

$             113

$        1,921

$        1,164

3,802

Taxes on Earnings (d)

(62)

Net Earnings

$       3,864

Diluted Earnings per Share

$         2.21

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.

c)

Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the NEC claims asserted on behalf of approximately 2,000 additional infants; approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve the United States Department of Justice (DOJ) investigations and the civil qui tam lawsuit brought by certain relators and joined by the DOJ and Attorneys General of several states; as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$            1

$            125

$       1,260

$           10

$       1,396

R&D

(1)

(42)

—

(40)

(83)

SG&A

(15)

(49)

—

6

(58)

Other (income) expense, net

(18)

—

—

(13)

(31)

Earnings before taxes

$           35

$            216

$       1,260

$           57

1,568

Taxes on Earnings (d)

(94)

Net Earnings

$       1,662

Diluted Earnings per Share

$        0.95

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

SOURCE Abbott

PALO ALTO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Broadcom Inc. (NASDAQ: AVGO), a global technology leader that designs, develops, and supplies semiconductors and infrastructure software, today announced the launch of Arcot Scam Defense, a groundbreaking new feature of Arcot by Broadcom, designed to block social engineering fraud during card-not-present (CNP) transactions.

“Financial institutions are experiencing broad increases in fraud attempts driven by sophisticated, AI-enhanced social engineering attacks,” said Matt Cooke, vice president and general manager, Payment Security Division, Broadcom. “While technological security systems have advanced and are highly effective at blocking fraud, fraudsters have pivoted their efforts to hacking customers directly. By impersonating trusted brands and institutions, they trick cardholders into revealing passwords or completing step-up authentications. Cardholders usually remain unaware that they have handed over the keys to the castle until after the scam.”

How Social Engineering Works
During a payment flow, once a cardholder completes a 3-D Secure authentication challenge, by entering a one-time password (OTP) or using a biometric, the transaction is treated as legitimate and is approved by a financial institution’s primary risk models. While real-time risk assessment models are highly effective at flagging suspicious transactions, they are not designed to stop a legitimate account holder actively under the influence of a scam.

Introducing Arcot Scam Defense  
“Arcot Scam Defense closes a critical gap,” added Cooke. “It serves as the definitive safety net against social engineering attacks. Operating as a real-time second layer of defense, it leverages advanced intelligence during authentication to flag suspected fraud – even after a successful challenge. By closing the approval door on these attacks, we increase cardholder safety and drive down fraud losses, while continuing to allow legitimate transactions through.”

Arcot Scam Defense analyzes a broad range of signals across transaction information, device intelligence, historical behavior, and the challenge interaction itself to identify patterns indicative of social engineering. These can include discrepancies in the location and behavior of the transacting checkout device and the authenticating device, delayed OTP entry, the use of an alternative authentication method, or a significant physical distance between the two devices. These signals are evaluated collectively to inform a real-time decision rather than relying on any single indicator. Additionally, the solution can integrate with third-party solutions to determine if the authenticating device is on an active phone call, which is a prime indicator of social engineering.

Even if a cardholder falls for a scam and hands over their credentials, Broadcom’s Arcot Scam Defense feature can help identify the behavioral shift and block the transaction in real time.

The scale of the problem is immense, with nearly half a billion dollars in fraud reported over the last 12 months on successfully authenticated challenges. In pilot testing validated on a full month of live data, the Arcot Scam Defense feature demonstrated exceptional performance. For one major pilot issuer, reviewing just the top 1% of successful challenges would have protected an estimated $4 million in fraud in just a month, at a cost of only 0.38 points off their authentication success rate.

Looking ahead, Broadcom expects to expand Arcot Scam Defense’s capabilities by adding new signals, including cardholder and device attributes, and a dedicated challenge history profiling engine to learn each cardholder's past challenge behavior.

Arcot by Broadcom is exclusively focused on 3-D Secure payment authentication. For more information on how Arcot is redefining payment security, visit https://www.broadcom.com/products/software/payment-security.

About Broadcom
Broadcom Inc. (NASDAQ: AVGO) is a technology leader that designs, develops, and supplies semiconductors and infrastructure software for global organizations' complex, mission-critical needs. Broadcom combines long-term R&D investment with superb execution to deliver the best technology, at scale. Broadcom is a Delaware corporation headquartered in Palo Alto, CA. For more information, visit www.broadcom.com.

Broadcom, the pulse logo, and Connecting everything are among the trademarks of Broadcom. The term "Broadcom" refers to Broadcom Inc., and/or its subsidiaries. Other trademarks are the property of their respective owners.

Press Contact:

Eloy Ontiveros
Broadcom Global Communications
+1.650.427.6145
[email protected]

Key Takeaways Stryker gains FDA clearance for Sonopet 3, with first clinical cases set for October and a fall 2026 launch.SYK shares gained more than 2% since the Oct. 14 announcement, despite a 7.1% year-to-date decline.Sonopet 3's RISE integration and Pulse Control aim to boost surgical efficiency, precision and adoption.
Stryker (SYK - Free Report) recently received FDA 510(k) clearance for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, the new system is designed to enhance surgical power, precision and workflow efficiency. The first clinical cases are expected to begin in October, with a full commercial launch anticipated later this fall.

The launch marks another step in Stryker’s efforts to strengthen its neurosurgical portfolio through product innovation and surgeon-focused technologies. The new platform could support customer engagement and create revenue growth opportunities as commercialization progresses. However, near-term financial contribution will likely depend on the pace of adoption, demand from hospitals and surgical centers, and the company's ability to translate the product's performance improvements into broader market penetration.

SYK Stock Trend Following the NewsFollowing the announcement on Oct. 14, SYK stock has gained more than 2% till yesterday’s close. Year to date, shares of the company have lost 13.4% compared with the industry’s 13.4% decline and the S&P 500’s 12% rise.

Stryker’s launch of Sonopet 3 could support its long-term growth by strengthening its neurosurgical portfolio and reinforcing its focus on surgeon-driven innovation. The platform’s enhanced power, precision and workflow integration could improve its appeal to surgeons and healthcare providers, supporting customer retention and adoption across surgical settings. Over time, successful commercialization could create incremental revenue opportunities and strengthen Stryker’s competitive positioning in the neurosurgery market.

SYK currently has a market capitalization of $108.02 billion.

Image Source: Zacks Investment Research

More on the NewsSonopet 3 was developed with feedback from hundreds of surgeons, with design improvements guided by their requirements for greater power, better ergonomics and enhanced integration in demanding surgical environments. The platform incorporates RISE, or Reimagined Integrated Surgical Experience, which is designed to support a more connected surgical workflow, and Pulse Control, which gives surgeons additional control over the removal of hard and soft tissues. These features are intended to improve usability and help streamline surgical workflows across different settings. According to Stryker, the enhancements reflect its focus on incorporating customer feedback into product development and advancing its neurosurgical technologies.

Stryker expects the first clinical cases using Sonopet 3 to begin in October, ahead of a full commercial launch anticipated later in fall 2026. The upcoming rollout will be an important step in gauging the platform's initial reception among surgeons and healthcare providers. Successful adoption could strengthen Stryker's competitive position in neurosurgery and create opportunities to deepen relationships with hospitals and surgical teams.

However, the company has not disclosed specific sales targets or the expected financial contribution from Sonopet 3. Its commercial impact will therefore depend on the pace of market adoption and the extent to which the new platform translates its performance and workflow enhancements into sustained customer demand.

Industry Prospects Favoring the MarketAccording to data provided by Persistence Market Research, the global neurosurgery market size is expected to be valued at $5.9 billion in 2026 and projected to reach $8.4 billion by 2033, expanding at a CAGR of 5.1% between 2026 and 2033.

The market is driven by the rise in global burden of neurological conditions, including traumatic brain injury, stroke, brain tumors and epilepsy, combined with rapid innovation in minimally invasive neurosurgical techniques, neuro-interventional devices and stereotactic radiosurgery systems.

Other NewsIn September, SYK announced an expansion of its Foot & Ankle portfolio, launching Prophecy Surgical Planning for the Incompass Total Ankle System and introducing Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures.

SYK’s Zacks Rank & Key PicksCurrently, SYK carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.

MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.

COLUMBUS, Ohio, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Root, Inc. (NASDAQ: ROOT), the leading technology company in car insurance, today announced that Root Insurance is now available in Wyoming, expanding its auto insurance availability to 38 states representing 81% of the U.S. population. The launch of Root Insurance in Wyoming advances the company toward its goal of providing coverage across the contiguous United States by the end of 2027.

Wyoming drivers can now get a Root car insurance quote, customize their coverage, and purchase a policy in just minutes, and manage their policy directly in the Root app. Root uses technology and data science to more precisely understand and price risk while creating a simple, digital insurance experience for customers.

“Launching in Wyoming brings us another step closer to making Root available to drivers across the country,” said Alex Timm, Root Founder and CEO. “We’ve built a technology and data science platform that allows us to enter new markets efficiently and give more consumers access to a personalized, easy insurance experience. Wyoming drivers can now get a quote and purchase coverage whenever they're ready, making it possible to get insured and on the road the same day. We're excited to bring that experience to more drivers as we continue expanding nationwide.”

Root car insurance is now available in Wyoming
Wyoming drivers can now shop for, purchase, and manage Root auto insurance digitally. Root offers Wyoming customers the ability to:

Get a Root insurance quote and purchase coverage in minutes: Wyoming drivers can get a quote and purchase a policy online in just minutes.Customize their auto insurance coverage: Customers can select from available coverage limits and deductibles to find a policy that fits their individual needs.Manage their policy digitally: Root customers can access insurance documents, make policy changes, and start a claim through the Root mobile app.Access Root through multiple channels: Root offers insurance directly to consumers and through a growing network of independent insurance agents and distribution partners. Root offers personal auto insurance in Wyoming, including liability, comprehensive, and collision coverage, subject to eligibility and availability.

Car insurance coverage options available in Wyoming

Root offers Wyoming drivers a range of car insurance coverage options to meet their needs and protect them on the road. Available coverages include:

Liability Coverage: Helps pay for injuries and property damage you cause to others in an accident.Collision Coverage: Helps pay to repair or replace your vehicle if it's damaged in a collision, regardless of fault.Comprehensive Coverage: Helps cover damage to your vehicle from events outside of collisions, including theft, vandalism, severe weather, and falling objects.
Wyoming drivers can customize their policies by selecting available coverage options, limits, and deductibles that fit their needs and budgets. Coverage options are subject to eligibility and availability.

Root expands car insurance availability to 38 states
Wyoming is the 38th state where Root offers auto insurance, following the company's expansion into New Jersey in July 2026. With this latest launch, Root now offers car insurance in states representing 81% of the U.S. population and continues working toward its goal of expanding across the contiguous United States by the end of 2027.

Root was founded in 2015 in Columbus, Ohio, with a focus on using technology, data science, and driving behavior to improve how car insurance is priced and experienced. Its technology platform supports efficient geographic expansion and allows Root to reach customers through its direct-to-consumer channel, independent insurance agents, and distribution partners.

How to get Root car insurance in Wyoming

Wyoming drivers can get a quote and purchase coverage through the Root mobile app or by visiting the Wyoming car insurance page. Drivers can also start a quote online.

No test drive is required to purchase a Root policy in Wyoming. Eligible drivers can get a quote, select their coverage, and purchase insurance immediately through Root's digital experience.

Coverage, discounts, and eligibility may vary. Root auto insurance in Wyoming is underwritten by Root Property & Casualty Insurance Company.

Frequently Asked Questions About Root Insurance in Wyoming

Is Root Insurance available in Wyoming?
Yes. Root Insurance is now available in Wyoming. Wyoming is the 38th state where Root offers car insurance, expanding its availability to states representing 81% of the U.S. population.

Can I get Root car insurance immediately in Wyoming?
Yes. Wyoming drivers can get a Root car insurance quote and purchase coverage immediately, without completing a test drive or waiting for a driving evaluation. Eligible drivers can purchase a policy online in just minutes.

Does Root Insurance require a test drive?
No. Root Insurance does not require a test drive to purchase car insurance. Drivers can get a quote online, customize their coverage, and purchase a policy right away.

How much can you save with Root Insurance in Wyoming?
Safe drivers who switch to Root Insurance can save up to $1,300 annually, subject to driving behaviors and chosen coverage levels.*

*Potential annual savings based on survey of actual customers who purchased a new Root policy in active markets between February 2025 - February 2026 and reported savings; changes in coverage levels not evaluated. Potential savings will vary.

What types of car insurance coverage does Root offer in Wyoming?
Root offers personal auto insurance in Wyoming, including liability, comprehensive, and collision coverage, subject to eligibility and availability. Drivers can explore available coverage options at Root's Wyoming car insurance page.

How can I get a Root car insurance quote in Wyoming?
Wyoming drivers can get a quote and purchase coverage through the Root mobile app or by visiting the Wyoming car insurance page. Drivers can also start a quote online.

Can I buy and manage my Root car insurance online?
Yes. Root provides a digital insurance experience that allows customers to purchase and manage policies, access insurance documents, make policy changes, and start a claim through the Root mobile app.

Is Root Insurance available through independent insurance agents in Wyoming?
Root's availability through independent insurance agents in Wyoming is subject to confirmation. Agents interested in selling Root Insurance can apply, begin the process and get appointed in as little as 24 hours.

How many states does Root Insurance operate in?
Root now offers auto insurance in 38 states, including Wyoming, representing 81% of the U.S. population. The company plans to expand across the contiguous United States by the end of 2027.

Where is Root Insurance available?
Root offers car insurance in 38 states, including Wyoming. Consumers can check availability in their state and explore coverage options online.

About Root, Inc.
Root Insurance is a technology company revolutionizing car insurance through data science and automation. Founded in 2015 and based in Columbus, Ohio, Root, Inc. (NASDAQ: ROOT) is the parent company of Root Insurance Company. The Root app has reached more than 18 million downloads and has analyzed more than 37 billion miles of driving data to deliver personalized, easy, and fair pricing. Root is available in 38 states and offers auto insurance to consumers across the United States through its direct-to-consumer channel, independent insurance agents, and distribution partners.

For more information, visit root.com.

Contacts
Media:
[email protected]

Root Inc, Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws regarding Root, Inc. These forward-looking statements relate to, among other things, expectations about our future business results, the success of our business in Wyoming, and our ability to complete our expansion into the contiguous U.S. by year-end 2027. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the company's control and are difficult to predict. We have based our forward-looking statements on our current expectations, estimates, and projections about our industry and our company. We caution that these statements are not guarantees of future performance and you should not rely unduly on them, as they involve risks, uncertainties, and assumptions that we cannot predict. Accordingly, our actual results may differ materially from the future performance that we have expressed or forecast. In accordance with “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we have included in Root's Form 10-K for the year ended Dec. 31, 2025, and other SEC filings, cautionary language identifying important factors that could cause future outcomes to differ materially from those set forth in the forward-looking statements. Copies of Root's Form 10-K and other SEC filings are available on the SEC's website, Root's website at ir.joinroot.com/investor-relations, or by contacting Root's Investor Relations office.

PJM assessment recognizes nearly all of FuelCell Energy’s installed capacity as dependable, an important proof point for reliability and potential capacity-market economics.  | Source: FuelCell Energy, Inc.

DANBURY, Conn., Oct. 21, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) announced that its FuelCell Energy Block System received a 99.873% rating in PJM Interconnection’s unit-specific Effective Load Carrying Capability (ELCC) assessment conducted as part of PJM’s 2028/29 Reliability Backstop Procurement (RBP) process. The result indicates that PJM may recognize nearly all of FuelCell Energy’s evaluated system’s capacity as dependable, providing an important measure of reliability for customers evaluating on-site power and informing potential participation in PJM’s capacity market.

Rapid data center growth is driving electricity demand and sharpening the focus on how large loads secure power. PJM projects 32 GW of peak load growth across its region from 2024 to 2030, with approximately 30 GW expected to come from data centers.1 As demand rises, large power users are increasingly considering generation that can provide dependable power where it is needed.

As communities hosting this growth place greater importance on how new electricity demand is met, FuelCell Energy’s carbonate fuel cell technology offers continuous, on-site generation that allows customers to locate power directly at the point of demand.

In practical terms, the 99.873% rating2 means PJM may count nearly 99.9 MW of every 100 MW evaluated as dependable capacity under the applicable assessment.

For context, preliminary PJM class ratings for the same 2028/2029 period recognize 96% of nuclear capacity, 93% of diesel utility/engine-based backup capacity and 67% of gas combustion turbine capacity.3

PJM’s unit specific assessment accredited 99.873% of the evaluated FuelCell Energy system’s capacity. PJM’s published technology class ratings provide a clear benchmark for the strength of that result. Following the Federal Energy Regulatory Commission's approval and delayed implementation of the Reliability Backstop Procurement (RBP), any future participation would be subject to PJM's applicable evaluation processes and could require updated accreditation using revised assumptions and study inputs for the final procurement timeline.

That reliability can have economic implications as well. For eligible projects in PJM, the amount of installed capacity recognized as dependable may affect the amount of capacity available for capacity-market participation and potential value, subject to applicable market requirements and auction or procurement outcomes.

“Customers aren’t simply looking for more megawatts. They need to understand how much power they can count on as they make decisions about where and how quickly they can grow,” said FuelCell Energy President & CEO Jason Few. “Our technology is designed to provide continuous, on-site distributed generation. This unit-specific assessment gives customers another independent measure of the dependability of our platform. It also has important economic implications: in PJM’s capacity market, the amount of installed capacity recognized as dependable directly influences the capacity a resource can potentially monetize. We believe a 99.873% accreditation highlights the potential for our platform to deliver not only highly dependable power, but attractive capital productivity for utilities and independent power producers deploying generation in PJM.”

Power That Counts

In addition to providing an independent measure of the evaluated system’s potential reliability contribution, capacity accreditation can have economic significance within PJM because it determines how much installed capacity is recognized as accredited capacity.

PJM uses ELCC to assess the reliability contribution of power resources and convert installed capacity (ICAP) into accredited capacity (UCAP). For eligible projects, higher accredited capacity may increase the amount of capacity available for capacity-market participation and potential value, subject to applicable market requirements and procurement or auction outcomes.

The 99.873% value is specific to the system evaluated for the 2028/2029 RBP process. It is not a FuelCell Energy technology-class rating or a measure of operating uptime, and future assessments may differ.

FuelCell Energy, Inc. (NASDAQ: FCEL) is an American clean energy technology company delivering continuous, scalable baseload power for mission-critical applications globally. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emissions power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems—backed by global fuel cell deployments approaching one gigawatt. Learn more at www.FuelCellEnergy.com. 

Contacts 

Media:                                                                                                                                                                        
Kathleen Blomquist 
[email protected] 
203.546.5844 

Investor Relations: 
[email protected]

_________________________

1 PJM Interconnection, “PJM Board Fast-Tracks Effort to Reliably Serve Large Loads,” PJM Inside Lines.
2 The 99.873% value is specific to the system evaluated for the 2028/2029 RBP process. It is not a FuelCell Energy technology-class rating or a measure of operating uptime, and future assessments may differ.
3 Preliminary ELCC Class Ratings for Use in the Reliability Procurement Backstop (RBP)

CareCredit Pay Later is CareCredit's enhanced installment loan product that will be presented digitally with CareCredit's revolving credit card to give consumers additional payment options and simplified offer comparisons.

Key Highlights:

Supporting providers and consumer choice: Offering more payment choices can help providers meet different consumer preferences, while CareCredit manages administrative and billing workflows.
One credit application. Two ways to pay: CareCredit Pay Later and the CareCredit credit card give eligible consumers two payment options to help manage care expenses.
Responsible credit access: Advanced underwriting through Synchrony PRISM evaluates overall active credit commitments to support responsible lending.
Payment predictability drives consumer decisions: 80% of surveyed consumers say payment options influence which provider they select, and 77% of consumers say having flexible payment options is critical when choosing a recommended treatment plan.
CareCredit stands apart: CareCredit is the only health and wellness financing platform and network that offers revolving credit, installment loans, promotional financing solutions, and broad provider acceptance across more than 290,000 healthcare locations nationwide.
, /PRNewswire/ -- CareCredit, a Synchrony (NYSE: SYF) solution, today launched CareCredit Pay Later, its enhanced and rebranded installment loan product that provides health and wellness consumers with a clear payment plan and defined payoff timeline to help budget for products and elective health and wellness expenses not covered by insurance. CareCredit Pay Later presents another option to CareCredit's existing credit card and offers another way for eligible consumers to plan and pay for care. It is available today at nearly 20,000 health and wellness locations, including select dental, cosmetic, vision, and audiology care providers, with expansion across CareCredit's entire network over time.

CareCredit Pay Later presents another option to CareCredit’s existing credit card and offers another way for eligible consumers to plan and pay for care. It is available today at nearly 20,000 health and wellness locations, including select dental, cosmetic, vision, and audiology care providers, with expansion across CareCredit’s entire network over time.

CareCredit Pay Later is CareCredit’s enhanced installment loan product that will be presented digitally with CareCredit’s revolving credit card to give consumers additional payment options and simplified offer comparisons.

Through a single credit application, eligible consumers can view the full array of CareCredit payment options available to them, so they can choose the product that best fits their budget, including:

CareCredit Pay Later: A one-time-use installment loan, offering fixed monthly payments, a clear payoff timeline, and a fixed APR for defined care expenses.
CareCredit Credit Card and CareCredit Rewards Mastercard®: Reusable revolving credit products that offer special financing options with convenient monthly payments, accepted across 290,000 locations nationwide, as well as select retailers, such as Albertson's, Walgreens and Walmart.

CareCredit Pay Later offers enhanced tools designed to make financing conversations even easier for providers and consumers. The payment calculator, available directly from the Provider Center portal homepage, now includes CareCredit Pay Later and uses each provider's specific promo mix to deliver more accurate estimated payment amounts. In addition, providers can now modify loan amounts before funding, creating greater flexibility to accommodate for treatment plan changes and helping ensure financing stays aligned with care decisions.

To ensure consumers are extended credit responsibly, CareCredit utilizes Synchrony PRISM®, Synchrony's proprietary underwriting platform. PRISM evaluates an applicant's broader financial health — looking beyond static credit scores to evaluate active lines of credit, debt-to-income indicators, and existing loan commitments that may not show on traditional credit reports. Consumers are encouraged to ask their participating CareCredit enrolled provider about the payment options that may be available to them, so they can make an informed decision. CareCredit Fair Financing Principles (FFP) initiative — designed to set a high standard for transparency and consumer education — connects consumers with product comparison guides, budgeting tools like CareCredit's procedure calculator, and an educational consumer guide managing commitments responsibly.

"In an industry where many treatments and products are elective, having flexible ways to pay for care is critical for consumers," said Adam Reinebach, CEO of the American Med Spa Association (AmSpa). "For med spa customers, having choices like the CareCredit credit card and CareCredit Pay Later can make it easier to move forward with the care they want, while benefiting from the confidence of paying through a trusted industry financing partner."

By providing tailored choices up front and allowing participating providers to easily customize promotions and then view, filter, and share available offers, this multi-product experience can help improve treatment conversion and acceptance, while CareCredit eases administrative burdens and helps simplify the payment process.

"When it comes to health and wellness, a 'one-size-fits-all' payment plan doesn't work for everyone," said Beto Casellas, Executive Vice President and Chief Executive Officer of Health & Wellness at Synchrony. "With CareCredit Pay Later, consumers now have more options to choose from based on their purchase, monthly budget, and preferences. By expanding these choices, we're empowering people to plan and pay for the care they want."

Research Shows Payment Clarity and Choice Matter When Planning and Paying for Care
The expanded offering comes as CareCredit consumer research reveals how strongly cost, payment clarity and choice can shape care experiences and decisions.

According to the research:

Cost clarity matters early. 58% of consumers worry about how much care will cost, and 51% say it's not always clear what out of pocket expenses will be.[1] In addition, 77% say knowing the total cost of care upfront is very or extremely important.1 
Payment experience can influence provider choice. 80% say payment options influence which provider they select,[2] and 50% would consider switching providers if billing became too cumbersome.1 
Credit access can help consumers move forward. 41% say they would likely postpone their care if they could not pay using credit, and 46% would postpone if they had to pay full price upfront.2
To learn more about CareCredit, visit https://www.carecredit.com/.

FAQ

What is CareCredit Pay Later?
CareCredit Pay Later is a single-use installment loan that offers eligible consumers a fixed APR, set monthly payments, and a defined payoff timeline to budget for specific health and wellness expenses.

How does Synchrony ensure CareCredit Pay Later is used responsibly? 
CareCredit utilizes Synchrony PRISM®, an advanced underwriting engine that looks at an applicant's complete financial picture. PRISM evaluates overall active debt commitments — including active loans across other platforms — to help ensure applicants are not taking on payments they cannot comfortably manage.

How is CareCredit Pay Later different from the CareCredit credit card?
CareCredit Pay Later is a single-use installment loan that closes once the balance is paid in full. The CareCredit credit card is a reusable line of credit offering deferred interest options and ongoing utility across more than 290,000 provider and retail locations nationwide.

How is CareCredit Pay Later different from Pay In Four?
CareCredit Pay Later offers consumers longer-term installment options with fixed monthly payments, a fixed APR, and defined payoff timelines designed to help budget for larger health and wellness expenses, whereas Pay in four plans typically split smaller purchases into four short-term, bi-weekly payments.

Will checking my eligibility impact my credit score?
No. Consumers can see if they prequalify for CareCredit financing options through a simple application with no hard credit check, meaning there is no impact to their credit score.

Where can I use CareCredit Pay Later?
CareCredit Pay Later is currently rolling out to nearly 20,000 participating health and wellness locations, including select dental, cosmetic, vision, and audiology providers, with planned expansions across CareCredit's network over time. Consumers are encouraged to ask their provider which CareCredit payment options are currently available at their practice.

Can I use a CareCredit Pay Later loan for multiple, ongoing treatments?
CareCredit Pay Later is designed as a single-use loan for a specific treatment, procedure, or purchase. For ongoing care wants and needs, elective care, and repeat use across our provider network, the CareCredit credit card remains an ideal reusable financing option.

How does offering CareCredit Pay Later benefit health and wellness providers and practices?
Because every consumer's financial situation is different, a "one-size-fits-all" approach to payments no longer works. By offering an expanded suite of payment options with a single application, providers can meet diverse consumer wants and needs and help more people say "yes" to recommended care. Furthermore, CareCredit manages all billing and collections, streamlining the payment experience for practice staff and protecting providers against payment delays and defaults.

About the Research
The findings cited in this release are drawn from two CareCredit consumer research studies: Well, Informed, which explored consumer attitudes and experiences related to healthcare costs and payment preferences, and Path to Purchase, which examined when and how payment information influences decisions across the healthcare journey. Respondents across both studies totaled 4,105. Additional methodological information is available upon request. 

About Synchrony
Synchrony (NYSE: SYF) is a leading consumer financing company that has been at the heart of American commerce and opportunity for nearly a century. Synchrony delivers credit and banking products that empower tens of millions of consumers to improve their financial lives and access what matters most. Leveraging innovative solutions that are shaping the future of retail commerce, Synchrony supports the growth and success of some of the nation's most respected brands, alongside hundreds of thousands of small and midsize businesses, including health and wellness providers. Committed to excellence in service and culture, Synchrony is honored to be ranked the #1 Best Company to Work For® in the U.S. by Fortune magazine and Great Place to Work®. For more information, visit www.synchrony.com.

Contact:
Michelle Romero
Synchrony
[email protected] 

*Mastercard and the circles design are registered trademarks of Mastercard International Incorporated.

_____________________________

1 

"Well Informed." CareCredit. May, 2026.

2

"2026 CareCredit Path to Purchase." CareCredit. March, 2026.

SOURCE Synchrony

FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today confirmed that its IQ® EV Charger 2 supports the ISO 15118-20 communication standard required under the European Union's Alternative Fuels Infrastructure Regulation (AFIR). The requirement takes effect on Jan. 1, 2027.

Under AFIR, newly installed or renovated public and private EV chargers in the EU must support ISO 15118-20, the protocol that governs secure communication between vehicle and charger and enables features such as automatic authentication, so charging starts as soon as the car is plugged in, and bidirectional charging, where supported by the vehicle and the charging setup. IQ EV Charger 2 has supported the standard since launch, so distributors and installers can keep offering it as is, with no part number changes or inventory adjustments. Chargers already installed at customer sites require no action to support the AFIR standard.

“We want to recommend a charging solution our customers can rely on for years,” said Fedde Tjalsma, solar service manager at Mensonides Installatie, an installer of Enphase products in the Netherlands. “With ISO 15118 support, Enphase is preparing its chargers for vehicle-to-grid capabilities down the road. That forward-looking approach is a big plus for us as an installer.”

“What especially appeals to me as an installer about the Enphase IQ EV Charger 2 is that they clearly looked beyond just charging an electric car,” said Kick Vermeulen, owner of Kick Power, an installer of Enphase products in the Netherlands. “With its focus on new technologies and communication standards such as ISO 15118, Enphase shows that it develops solutions not only for today, but also for the energy world of tomorrow. That makes the IQ EV Charger 2 a future-proof choice for me.”

"Regulations will keep evolving, and our customers shouldn't have to chase them," said Jayant Somani, senior vice president of the digital business unit at Enphase Energy. "IQ EV Charger 2 was ready for ISO 15118-20 from day one. Installers can choose it with confidence, and we're inviting automakers to test with us so drivers can get the most out of their home energy."

Enphase plans to continue releasing over-the-air firmware updates to add new features and expand vehicle compatibility, so installers and homeowners can get more from the same hardware they put in on day one.

Distributors and installers can contact their Enphase sales representative to learn more about IQ EV Charger 2 compatibility with AFIR. For more information about the IQ EV Charger 2, please visit the regional websites (Netherlands, France, Germany, Norway). To access Enphase Energy’s self-declaration of compliance with AFIR, visit the Documentation section of the relevant product pages and open the document titled “ISO 15118-2 / ISO 15118-20 Protocol Support and Testing.”

About Enphase Energy, Inc.

Enphase Energy is a global energy technology company advancing intelligent power systems for homes, businesses, and next-generation AI data centers. The company designs semiconductor-based energy technologies spanning solar, batteries, EV charging, energy management, and virtual power plants, and is developing solid-state transformer technology to address the rapidly growing power demands of AI data centers. Based in Fremont, California, Enphase is the world’s leading supplier of microinverter-based solar and battery systems. The company revolutionized the solar industry with its microinverter technology and has shipped approximately 89.4 million microinverters, with approximately 5.3 million Enphase-based systems deployed in more than 165 countries. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. For more information, visit https://enphase.com/.

©2026 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements related to the expected capabilities and performance of Enphase Energy's IQ EV Charger 2, including safety, quality, reliability, and interoperability; the ability of IQ EV Charger 2 to support the ISO 15118-20 communication standard and comply with the requirements of the AFIR; Enphase Energy's plans to support additional vehicle interoperability and functionality through testing programs and over-the-air firmware updates; and the expected benefits of future software enhancements and expanded vehicle compatibility. These forward-looking statements are based on Enphase Energy's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, market demand for EV charging solutions and related products; competitive developments; changes in electric vehicle adoption rates; changes in regulatory, certification, interoperability, or compliance requirements, including AFIR requirements; compatibility with third-party vehicles, energy systems, software platforms, and charging standards; product performance and reliability under actual operating conditions; supply chain availability and costs; and other factors discussed in Enphase Energy's filings with the Securities and Exchange Commission, including those risks described in more detail in Enphase Energy's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

Contact:

Enphase Energy
[email protected]

Hledat v komentářích

Investiční doporučení

Výsledky společností - ČR

Výsledky společností - Svět

IPO, M&A

Týdenní přehledy

Detail - články

21.10.2026 15:30

SAB Finance a.s.
IČ 247 17 444

Představenstvo společnosti SAB Finance a.s., IČO 247 17 444, se sídlem Na Příkopě 969/33, 110 00 Praha 1 – Staré Město, Česká republika, zapsané v obchodním rejstříku vedeném Městským soudem v Praze pod spis. zn. B 16383, v souvislosti s pověřením valné hromady ke zvýšení základního kapitálu upisováním nových akcií na majitele v zaknihované podobě ze dne 18. září 2026 uveřejňuje, že:

v rámci první fáze úpisu bylo upsáno 547.596 kusů akcií a do druhé fáze přechází 395.801 kusů akcií.

Zpráva je dostupná také na webu https://www.sab.cz/pro-investory#aktuality.

(komerční sdělení)

Tagy: Povinně uveřejňované informace
Reklama

Na tomto místě můžete zahájit diskusi. Zatím nebyl zadán žádný názor. Do diskuse mohou přispívat pouze přihlášení uživatelé (Přihlásit). Pokud nemáte účet, na který byste se mohli přihlásit, registrujte se zde.

Aktuální komentáře

21.10.2026 15:30SAB Finance a.s.: Veřejná nabídka nových akcií SAB Finance a.s. – druhá fáze úpisu 15:18CSG představila obojživelné vozidlo Meander. Novinka zvládne převézt až 70 vojáků 14:35SpaceX už není jen vesmírný příběh. Hlavním motorem růstu se stává AI   13:01Reklama se zadrhla, obsah tolik neláká a Netflix poprvé po letech hledá nový motor růstu   12:07Evropa obchoduje lehce v plusu, zatímco SpaceX zlepšila sentiment kolem polovodičů   11:55Getty Images požádala v USA o ochranu před věřiteli, zahájila restrukturalizaci 11:27PODCAST Rozhovory s Václavem Svátkem: AI je revoluce, ale investiční bublina může prasknout 10:11Anthropic by mohl za výpočetní výkon utratit až 750 miliard dolarů, v první polovině roku vykázal ztrátu přes 80 miliard 9:05Rozbřesk: Strach z dluhů AI firem změnilo chování hlavních trhů. Ale na jak dlouho? 8:49Optimismus vrací. Trhy podpořily výsledky SpaceX a Super Micro   8:27SpaceX překvapila rekordním ziskem. Musk poprvé veřejně připustil fúzi s Teslou 20.10.2026 22:29Netflix doručil tržby v souladu s očekáváním, ve zbytku roku ale očekává další zpomalení růstu 22:04Wall Street hledá pevnější půdu pod nohama. Rozhodnou výsledky a návratnost investic do AI   17:19Čekání na obrat v investičním boomu se nemusí vyplatit 16:17Plyn v Evropě zdražil nejvíce od roku 2022. Trh se obává nové energetické krize   15:29Facebook, TikTok i YouTube pod tlakem. Austrálie chystá žaloby kvůli porušování zákazu pro mladistvé 15:02Překonání odhadů ani oznámený zpětný odkup akcií nepomohl. Akcie GM po výsledcích klesají o sedm procent 13:31Fidelity: Kde hledat příležitosti mimo technologické giganty 12:07AMISTA investiční společnost, a.s.: TMR Fond SICAV a.s. - Pololetní finanční zpráva od 1. 1. 2026 do 30. 6. 2026 12:01Preview Mety: Trh zajímá monetizace AI a síla reklamního byznysu
Reklama

Související komentáře

Nejčtenější zprávy dne

Nejčtenější zprávy týdne

Nejdiskutovanější zprávy týdne

Kalendář událostí

Nebyla nalezena žádná data

Potřebujte poradit?

Louisbourg Investments Inc. reduced its position in shares of Salesforce Inc. (NYSE:CRM – Free Report) by 28.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 48,717 shares of the CRM provider’s stock after selling 19,449 shares during the quarter. Salesforce accounts for about 1.9% of Louisbourg Investments Inc.’s investment portfolio, making the stock its 13th biggest holding. Louisbourg Investments Inc.’s holdings in Salesforce were worth $11,184,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CRM. BlackRock Inc. purchased a new stake in shares of Salesforce during the second quarter valued at approximately $11,396,844,000. Arrowstreet Capital Limited Partnership raised its holdings in Salesforce by 130.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 12,659,217 shares of the CRM provider’s stock worth $2,363,096,000 after acquiring an additional 7,160,302 shares during the last quarter. Bank of America Corp DE purchased a new position in Salesforce in the 2nd quarter worth approximately $1,914,086,000. Legal & General Group Plc purchased a new position in Salesforce in the 2nd quarter worth approximately $927,332,000. Finally, Bank of New York Mellon Corp bought a new position in Salesforce in the 2nd quarter valued at approximately $844,928,000. Institutional investors own 80.43% of the company’s stock.

Salesforce News Summary Here are the key news stories impacting Salesforce this week:

Positive Sentiment: Salesforce agreed to acquire customer-engagement software provider Braze (NASDAQ: BRZE) for approximately $5.66 billion, paying $47.50 in cash per Braze Class A share—a premium of roughly 58%. Braze’s real-time marketing and customer-engagement tools could strengthen Salesforce’s AI-powered CRM and marketing offerings. Salesforce Signs Definitive Agreement to Acquire Braze Positive Sentiment: The transaction could help Salesforce expand its data and AI monetization strategy by combining Braze’s behavior-based engagement platform with Salesforce’s customer data, automation and agent technology. Rival Klaviyo’s advance suggests investors see broader strategic value for the customer-engagement software sector. Salesforce Buying Customer Engagement Firm Braze Positive Sentiment: Salesforce’s longer-term outlook remains supported by its AI-agent ambitions and enterprise data assets, including Informatica. One bullish analysis argues the shares could deliver substantial gains by 2030 if AI adoption accelerates and the company converts its installed base into recurring revenue. I Ran the Numbers on Salesforce: Here’s Where I Think It Could Be in 2030 Neutral Sentiment: The Braze deal is a strategic bet rather than an immediate earnings catalyst. Investors will look for details on funding, closing conditions, integration, revenue synergies and whether the acquisition improves Salesforce’s growth rate. Negative Sentiment: The cash purchase price and sizable premium raised concerns about capital allocation and whether Salesforce is overpaying in an increasingly competitive marketing-software market. Those concerns caused CRM shares to retreat initially despite the potential AI benefits. Salesforce Announces $5.66 Billion Deal for Braze Insiders Place Their Bets In other Salesforce news, Director Craig Conway sold 4,500 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $260.61, for a total value of $1,172,745.00. Following the transaction, the director owned 5,437 shares of the company’s stock, valued at approximately $1,416,936.57. This represents a 45.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Blair Kirk bought 4,176 shares of the company’s stock in a transaction on Friday, September 18th. The stock was purchased at an average cost of $239.33 per share, for a total transaction of $999,442.08. Following the completion of the transaction, the director directly owned 18,748 shares of the company’s stock, valued at approximately $4,486,958.84. The trade was a 28.66% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.50% of the stock is currently owned by corporate insiders. Salesforce Price Performance Shares of CRM opened at $242.77 on Wednesday. The firm has a market cap of $199.80 billion, a PE ratio of 22.13, a P/E/G ratio of 1.10 and a beta of 1.26. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 1.02. The firm has a fifty day simple moving average of $233.29 and a two-hundred day simple moving average of $195.68. Salesforce Inc. has a 1-year low of $146.32 and a 1-year high of $269.11.

Salesforce (NYSE:CRM – Get Free Report) last released its quarterly earnings results on Wednesday, August 26th. The CRM provider reported $5.90 earnings per share for the quarter, beating the consensus estimate of $3.27 by $2.63. The firm had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $11.33 billion. Salesforce had a return on equity of 24.90% and a net margin of 21.99%. The company’s revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.91 EPS. Salesforce has set its FY 2027 guidance at 16.670-16.710 EPS and its Q3 2027 guidance at 3.420-3.440 EPS. On average, equities analysts anticipate that Salesforce Inc. will post 12.82 EPS for the current year.

Salesforce Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Investors of record on Thursday, September 17th were given a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Thursday, September 17th. Salesforce’s dividend payout ratio is 16.04%.

Analyst Ratings Changes Several analysts have commented on the company. Wells Fargo & Company downgraded Salesforce from a “buy” rating to a “strong sell” rating in a research note on Monday, October 12th. Citizens Jmp reissued a “market outperform” rating and issued a $315.00 target price on shares of Salesforce in a report on Friday, September 18th. Susquehanna began coverage on Salesforce in a research note on Wednesday, July 1st. They issued a “neutral” rating for the company. JPMorgan Chase & Co. upped their price target on Salesforce from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. Finally, CLSA began coverage on Salesforce in a report on Monday, July 20th. They set a “hold” rating and a $165.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, thirty-two have issued a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.40.

View Our Latest Analysis on Salesforce

Salesforce Company Profile (Free Report)

Salesforce, Inc (NYSE: CRM) is a global enterprise software company that provides cloud-based customer relationship management (CRM) technology. Its platform helps organizations manage sales, customer service, marketing, commerce, data, analytics and interactions with customers across digital and traditional channels.

The company’s products include Sales Cloud, Service Cloud, Marketing Cloud, Commerce Cloud and Data Cloud. Salesforce also offers Tableau for data visualization and analytics, MuleSoft for application integration, and Slack for workplace collaboration.

Read More Five stocks we like better than Salesforce Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding CRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Salesforce Inc. (NYSE:CRM – Free Report).

Receive News & Ratings for Salesforce Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salesforce and related companies with MarketBeat.com's FREE daily email newsletter.

DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and discovery

The tools automate end-to-end informatics processes at scale and help customers build private data lakes to drive scientific and clinical research insights

, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced three early-access capabilities on its BioInsight Platform that help researchers move faster from sequencing data to discovery. BioInsight Platform Workflow Orchestrator enables laboratories to operate consistent, traceable sequencing and informatics operations at scale. DRAGEN Ultra extends genomic analysis beyond variant calling, using Illumina AI models and knowledge resources to prioritize candidate variants, and sort large numbers of research samples. BioInsight Platform Learning Cohorts, paired with the previously announced BioInsight Data, helps researchers investigate patterns across large genomic, multiomic, and phenotypic datasets, placing individual findings in their more informative biological and population context.

The new Workflow Orchestrator is designed to run each genomic analysis as a connected process, from sample tracking, through sequencer run planning, secondary analysis, quality control, and tertiary software for insight generation.

DRAGEN Ultra extends genomic analysis beyond variant calling by combining Illumina genomic AI models and proprietary knowledge resources to help prioritize variants for further investigation.

The Learning Cohorts tool will help researchers move beyond single sample evaluation and into dynamic knowledge generation in which every sample informs future discovery.

Together, the capabilities help research organizations operate consistent, efficient genomic workflows at scale, focus investigation on the samples and variants that matter, and place those findings in the context of larger genomic and multiomic populations.

"The promise of genomics depends on generating vast and complex data, then distilling that data into insights that advance discovery," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. "Researchers need consistent, scalable, reproducible workflows, AI that helps identify the samples and findings that matter most, and the ability to study those samples across increasingly large and diverse cohorts. We've put all our new development energy into new capabilities to make it easy to scale insight generation, so research organizations can focus on advancing the science rather than assembling and maintaining software."

The Illumina BioInsight Platform, which debuted last week, offers a suite of genomic and multiomics software tools and data sources. Researchers can choose the capabilities they need and link them together, designing workflows that best suit their science and adding capabilities as their programs grow.

BioInsight Platform Workflow Orchestrator enables connection to Illumina sequencers for automated, scaled genomics operations

As datasets grow and workflows become more complex, research organizations need consistent quality, reproducibility, and traceability at every stage of sequencing and analysis.

The new workflow orchestration software is designed to run each genomic analysis as a connected process, from sample tracking, through sequencer run planning, secondary analysis, quality control, and tertiary software for insight generation. A visual workflow builder allows customers to start from an Illumina authored template and configure specific parameters to reflect their individual lab innovations. Lab scientists define the workflow and the software executes it efficiently, consistently, and compliantly across tens of thousands of samples, enabling teams to scale operations without adding complexity.

In Workflow Orchestrator, each sample maintains a single identity across software tools, providing complete result lineage covering the inputs, software versions, settings, and quality metrics that produced them. This gives research organizations a reproducible, audit-ready operational foundation for genomic analysis.

DRAGEN Ultra extends analysis beyond variant calling 

For over a decade, DRAGEN has provided industry leading performance, accuracy, and capabilities in the field of genomic secondary analysis. The new DRAGEN Ultra capability extends genomic analysis beyond variant calling by combining Illumina genomic AI models and proprietary knowledge resources to help prioritize variants for further investigation, accelerating the path from variant identification to genomic insights. DRAGEN Ultra is available on the Illumina BioInsight Platform as well as customer premises, private clouds, and air-gapped environments.

Now in early access, the technology is designed to support a range of research applications, including rare disease, population genomics, and multiomic studies. By integrating annotation and prioritization with variant calls, DRAGEN Ultra provides more complete insights for large scale projects.

DRAGEN Ultra will include dnaAI, a new variant prioritization model that predicts which variants are most likely to explain an observed phenotype. Developed by the BioInsight AI Lab, the new model was featured in a plenary session at ASHG, where Illumina revealed early research findings from the model. Applying dnaAI to large scale datasets resulted in an 8% increase in disease associations across unsolved cases. The model also ranked previously established disease-associated variants among its top four candidates in 99.4% of genomes analyzed. In addition to the new dnaAI feature, DRAGEN Ultra also draws on Illumina models designed to address distinct classes of biological variation, including PrimateAI-3D, PromoterAI, and the newly announced SpliceAI2.

BioInsight Platform Learning Cohorts tool reveals patterns beyond the individual sample 

The Learning Cohorts tool, also in early access, will help researchers move beyond single sample evaluation and into dynamic knowledge generation in which every sample informs future discovery. Researchers can explore genomic, multiomic, and associated phenotypic data across large private sample collections, compare individual observations with broader populations, and investigate associations that may not be visible within any one sample. The Learning Cohorts tool makes capabilities available to private researchers that were traditionally only available with large public cohorts.

Researchers can begin with a scientific question, identify relevant populations from available datasets, and dynamically build cohorts for further analysis. For example, a researcher investigating a rare variant can identify subjects sharing similar genomic features or phenotypes, compare outcomes across groups, and explore associations that may warrant further study. This approach supports a shift from executing analyses on predetermined groups to discovering and investigating populations at scale.

Previously announced BioInsight Data adds curated reference datasets that researchers can use to enrich institutional cohorts and place findings in broader biological and population contexts. Together, the Learning Cohorts tool and BioInsight Data allow researchers to examine patterns across datasets, generate new hypotheses, and build research resources that become more informative as additional genomic, multiomic, and phenotypic data are added.

The three new applications are available for early access customers via the Illumina BioInsight Platform.

Illumina introduced the capabilities at the annual meeting of the American Society of Human Genetics (ASHG) in Montréal.

ASHG attendees can learn more about DRAGEN Ultra, BioInsight Workflow Orchestrator, and Learning Cohorts at Illumina booth #701 and during Illumina's Industry Education session on Friday, Oct 23, 12:15 PM–1:15 PM (ET) in Room 513 ABC. Learn more about the Illumina BioInsight Platform here.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. 

Contacts
Investors:
Illumina Investor Relations
858-291-6421
[email protected]

Media:
Christine Douglass
[email protected]

SOURCE Illumina, Inc.

CHICAGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- TransUnion (NYSE: TRU) today announced the launch of Transaction Matching, a solution that connects transaction activity to persistent, privacy-conscious customer identities. The offering leverages Fiserv’s Unknown Shopper solution to help merchants recognize previously unidentified shoppers, including loyalty members who paid with a new card, or shoppers who paid using tap-to-pay or mobile wallet.

Merchants can then enrich pseudonymized customer profiles with demographic and lifestyle insights to better understand purchasing behavior and deliver more relevant offers.

“Transaction Matching helps merchants recognize more of the customers they already serve,” said Brian Silver, EVP of Global Marketing Solutions at TransUnion. “By connecting transaction activity with pseudonymized customer profiles, merchants can reduce duplicate records, better understand the customer journey and apply those insights across advertising, analytics and measurement.”

This is the first collaboration under TransUnion’s broader Transaction Matching solution, giving merchants a new way to unlock the value of customers who have traditionally been overlooked. It empowers merchants and brands to:

Bring unknown shoppers into focus: Connect previously unidentified in-store transactions to persistent customer identities.
Separate new customers from repeat customers: Identify returning customers who use a different payment card and measure new-customer acquisition more accurately.
Enrich customer profiles: Add demographic and lifestyle insights to help improve customer analysis and engagement.
Reduce payment method blind spots: Associate different card-based payment methods, inclusive of debit and credit card dip and swipe, tap-to-pay, and mobile wallet, with a single customer profile.
“Before partnering with TransUnion and Fiserv, a new credit card could look like a new customer, even when it belonged to a loyalty member,” explained Alisa Stewart, Director of Customer Relationship Management at Red Lobster. “Now we can easily distinguish new customers from returning guests and combine behavioral and demographic insights to better understand and engage them.”

Connecting customer intelligence across commerce and advertising
The collaboration connects complementary transaction and identity capabilities across the advertising and commerce ecosystems. This gives merchants a more complete view of customer activity while maintaining privacy-conscious controls.

“Many merchants have an incomplete view of their customers because transactions can appear disconnected across cards and payment methods,” said Prasanna Dhore, Chief Data Officer at Fiserv. “By working with TransUnion, we’re helping brands like Red Lobster recognize more of the customers already transacting with them, distinguish new customers and turn those insights into smarter marketing and growth decisions.” 

To learn more about TransUnion’s Marketing Solutions, click here.

About TransUnion (NYSE: TRU)
TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments, we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.
http://www.transunion.com/business

ContactDave Blumberg
TransUnion
  [email protected]  Telephone312-972-6646

New York, New York--(Newsfile Corp. - October 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026 (the "Class Period").

CLICK HERE TO JOIN THE CASE

If you are an investor in Chemours and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than December 7, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

According to the complaint, on August 4, 2026, after market, Chemours announced second quarter 2026 financial results. Among other things, the Company allegedly reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management allegedly admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; and (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable.

CLICK HERE TO LEARN MORE

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/the-chemours-company-cc-class-action/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320133

Source: Kaplan Fox & Kilsheimer LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Diversify Advisory Services LLC acquired a new stake in Marvell Technology, Inc. (NASDAQ:MRVL – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 159,393 shares of the semiconductor company’s stock, valued at approximately $38,452,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Marvell Technology by 34.1% in the second quarter. BlackRock Inc. now owns 85,641,174 shares of the semiconductor company’s stock valued at $25,511,649,000 after buying an additional 21,798,190 shares during the last quarter. State Street Corp lifted its stake in shares of Marvell Technology by 79.3% in the second quarter. State Street Corp now owns 41,834,272 shares of the semiconductor company’s stock worth $12,462,011,000 after buying an additional 18,495,866 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Marvell Technology in the second quarter worth about $2,607,795,000. Bank of New York Mellon Corp lifted its stake in shares of Marvell Technology by 153.3% in the second quarter. Bank of New York Mellon Corp now owns 7,957,985 shares of the semiconductor company’s stock worth $2,370,604,000 after buying an additional 4,815,725 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in Marvell Technology during the second quarter worth about $1,742,526,000. Hedge funds and other institutional investors own 83.51% of the company’s stock.

Insiders Place Their Bets In related news, COO Chris Koopmans sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $180.50, for a total value of $1,805,000.00. Following the transaction, the chief operating officer directly owned 227,941 shares in the company, valued at approximately $41,143,350.50. This represents a 4.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Justin Scarpulla sold 1,100 shares of the stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $273.59, for a total value of $300,949.00. Following the completion of the transaction, the chief accounting officer owned 909 shares of the company’s stock, valued at $248,693.31. The trade was a 54.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 57,285 shares of company stock valued at $12,837,063. Insiders own 0.12% of the company’s stock.

Trending Headlines about Marvell Technology Here are the key news stories impacting Marvell Technology this week: Positive Sentiment: Analysts and investors remain optimistic about Marvell’s AI opportunity. Coverage highlights robust demand for AI infrastructure products, improving long-term revenue visibility, and the company’s reported six-year, $120 billion agreement with Alphabet. Is Marvell Technology a Millionaire-Maker Stock? Positive Sentiment: GF Securities said a reported delay to Google’s next tensor processing unit should not materially damage Marvell’s position among custom-chip suppliers, helping ease concerns about near-term project timing. Marvell Jumps as Google Chip Delay Is Viewed as Manageable Positive Sentiment: Recent analyst support, including a fair-value increase tied to AI growth expectations, is reinforcing the bullish case for MRVL. Marvell Stock Sees Fair Value Lift Positive Sentiment: Marvell’s upcoming dividend payment provides a modest income-related catalyst and may attract investors seeking exposure to semiconductor infrastructure. Marvell to Pay Dividends Next Week Analyst Ratings Changes Several analysts recently issued reports on the stock. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Marvell Technology in a research note on Tuesday, October 6th. Royal Bank Of Canada raised their target price on shares of Marvell Technology from $360.00 to $425.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. The Goldman Sachs Group reissued a “neutral” rating and issued a $270.00 target price on shares of Marvell Technology in a research note on Wednesday, October 7th. Needham & Company LLC boosted their target price on Marvell Technology from $300.00 to $400.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Finally, KeyCorp restated an “overweight” rating on shares of Marvell Technology in a research report on Wednesday, October 7th. Three research analysts have rated the stock with a Strong Buy rating, thirty have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $327.36.

View Our Latest Research Report on Marvell Technology

Marvell Technology Price Performance Marvell Technology stock opened at $240.42 on Wednesday. Marvell Technology, Inc. has a 12-month low of $70.68 and a 12-month high of $329.88. The stock has a market cap of $210.82 billion, a P/E ratio of 79.35, a PEG ratio of 7.07 and a beta of 2.26. The company has a 50-day moving average price of $242.27 and a 200 day moving average price of $218.93. The company has a current ratio of 3.17, a quick ratio of 2.62 and a debt-to-equity ratio of 0.27.

Marvell Technology (NASDAQ:MRVL – Get Free Report) last issued its earnings results on Thursday, August 27th. The semiconductor company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.01. Marvell Technology had a net margin of 27.93% and a return on equity of 13.57%. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same period in the previous year, the firm earned $0.67 earnings per share. Marvell Technology’s quarterly revenue was up 36.5% compared to the same quarter last year. Marvell Technology has set its Q3 2027 guidance at 1.050-1.150 EPS. Sell-side analysts anticipate that Marvell Technology, Inc. will post 3.05 earnings per share for the current year.

Marvell Technology Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Thursday, October 29th. Stockholders of record on Friday, October 9th will be given a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 0.1%. The ex-dividend date of this dividend is Friday, October 9th. Marvell Technology’s payout ratio is presently 7.92%.

(Free Report)

Marvell Technology, Inc (NASDAQ: MRVL) is a semiconductor company that develops infrastructure solutions for data centers, telecommunications networks, enterprise systems, automotive applications and other connected markets. Its products are designed to support the movement, processing, storage and security of data across complex computing and communications environments.

The company’s portfolio includes data-processing and networking processors, custom application-specific integrated circuits, Ethernet switches and controllers, storage controllers, connectivity products, and electro-optics solutions.

See Also Five stocks we like better than Marvell Technology Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding MRVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marvell Technology, Inc. (NASDAQ:MRVL – Free Report).

Receive News & Ratings for Marvell Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marvell Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Software maker Paycom Software, Inc. (PAYC) rises 620% since 2015’s first outlier inflow signal, being revived by institutional interest.

PAYC develops and sells cloud-based software for human resources management, providing data and analytics to manage the full employment cycle. The company’s second-quarter 2026 report showed revenue of $531 million (a 10% year-over-year gain), GAAP net income of $107 million or $2.34 per diluted share (a 20% jump), returned $346 million to shareholders through repurchases, and increased full-year revenue and adjusted EBITDA guidance to a high end of $2.212 billion and $1.022 billion, respectively. The company reports again on Nov. 4.

It’s no wonder PAYC shares are up 65% this year – and they could rise more. MoneyFlows data shows how Big Money investors are once again betting heavily on the forward picture of the stock.

Big Money Rushes to Paycom Institutional volumes reveal plenty. In the last year, PAYC has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in PAYC shares. They reflect our proprietary inflow signal, pushing the stock higher:

Institutional inflows returning in the spring of 2026 sent PAYC shares up 65% so far in 2026. Source: www.moneyflows.com Plenty of technology names are under accumulation right now. But there’s a powerful fundamental story happening with Paycom.

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, PAYC has had strong sales and earnings growth:

3-year sales growth rate (+14.4%) 3-year EPS growth rate (+21.3%) Source: FactSet

Also, EPS is estimated to ramp higher this year by +15.6%.

Now it makes sense why the stock has been generating Big Money interest again. PAYC has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Paycom has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Outlier 20 report 64 times since 2015, gaining 620% in that time. The blue bars below show when PAYC was a top pick this year…institutions are still buying:

PAYC shares have attracted 64 outlier inflow signals since 2015 (620% gain), including two in 2026. Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

The PAYC revival isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds long positions in PAYC in personal and managed accounts at the time of publication.

If you are a Registered Investment Advisor (RIA) or a serious investor, take your investing to the next level. MoneyFlows created 11 Frontiers indexes to help serious investors capture AI-driven themes and learn the leading stocks in each Frontier. Get started here.

About the Author

Lucas is a well-versed equity investor and educator. He currently is co-founder of research and analytics firm, MAPsignals.com, which focuses on finding outlier stocks by following the Big Money.